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Abstract 
 
Although the current system of blood transfusion is relatively safe and established 
within the UK, periodic shortages of certain blood groups and residual risks of 
emerging transfusion transmitted infections (TTIs) make an industrial manufacture 
process for the generation of red blood cells more desirable. The generation of red blood 
cells from human embryonic stem cells has been completed in vitro but the major 
challenge lies in making the process highly scalable and economically viable.  
Initially human embryonic and induced pluripotent stem cells were trialled for use on 
the project however these were found to be inconsistent, a major issue in cellular 
therapies. They were replaced with CD34+ cord blood stem cells which are 
morphologically and physiologically divergent. In order to assess their suitability for a 
GMP-complaint manufacturing process an ultra-scale down (microfluidic) approach 
was taken to assess the cells’ reactions to the changeable physical environment 
associated with scale-up procedures.  Cellular responses to hypoxia and shear stress 
were evaluated at successive time-points in the step-wise haematopoietic differentiation 
process and recommendations made for optimum scale-up conditions. Conversely 
further challenges in the manufacture of red blood cells from stem cells were uncovered 
regarding the differences between stem cell derived red blood cells and their adult 
equivalents.  
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Chapter 1 - Introduction 
 
 
Blood transfusion involves the intravenous transfer of whole blood or its components 
from one person to another. In the case of red blood cell transfusion, cells may be 
administered as part of whole blood but are more often separated from other blood 
components (white blood cells, platelets and plasma) as red cell concentrates [1]. 
Red cell transfusion is an essential medical procedure used to treat blood loss following 
surgical procedures or trauma and treat anaemia or haemorrhage associated disorders. 
These diverse applications place high demand on stocks with around 2.2 million units of 
blood component used in the UK each year [2]. Stocks are currently maintained through 
altruistic donation of anonymous individuals who have corresponding blood type to the 
recipient or who have the universal blood donor type, O negative.  
The current system is normally efficient and sustainable yet there are several 
uncertainties over whether service can be maintained indefinitely since numerous 
external factors have a direct negative impact on its operation. Stringent eligibility 
criteria, short shelf life, proportional inconsistencies of blood groups in the population 
and interruptions of normal service by holiday periods and state events result in 
shortened and/or erratic supply [2]. Pressure will only increase with the population’s life 
expectancy on an already laboured system. 
Furthermore, despite rigorous donor health checks and sensitive serological and nucleic 
acid screening for transfusion transmitted infections (TTIs) there are residual risks with 
blood transfusion. Transmission of highly infectious, occasionally fatal viruses HIV and 
Hepatitis B and C still occur, particularly in developing countries where infection rates 
are higher and screening is not as widely accessible [3]. Novel TTIs continue to emerge 
and are readily spread by international travel and trade placing potential risk on the 
system for years to come [4]. 
There is then ample motivation for a replacement or supplement product for red blood 
cell donation which will ensure its safety and supply. The generation of manufactured 
red blood cells from stem cells is emerging as an attractive solution to these problems. 
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1.1 Stem cells for use in cellular therapies 
 
Regenerative Medicine describes the process by which human cells, tissues or organs 
are replaced or regenerated in order to restore normal function.  Cellular therapy, a sub 
category of regenerative medicine, is a form of medical or surgical treatment in which 
new cells are introduced to a tissue in order to treat or prevent a disease. 
The discipline has undergone recent and rapid expansion due to unprecedented 
applications in tissue regeneration and repair through the use of stem cells. These cells 
have the ability to self-renew as well as differentiate into a number of different cell 
types [5].   
 
 
1.2 Good manufacturing process 
 
Good manufacturing process (GMP) is a regulatory system for ensuring that 
commercial therapeutic products are produced in accordance with quality standards and 
meet the guidelines set down by the relevant licensing and regulatory authorities.  
Products must be of consistently high quality, have a specific action and be appropriate 
for the intended use. This is crucial for cellular therapies whereby cells or their products 
are administered directly to a patient putting them at risk of immune rejection [6], 
teratoma [7], disease [8] and other undesirable responses. It is therefore imperative that 
the manufacture of cell therapy products is robust and reproducible so that the 
physiological response is predictable. It is also desirable that the manufacturing process 
be xeno-free to protect from cross-contamination [9] and that superfluous proteins and 
nucleic acids [10] be removed to prevent immune rejection and development of 
teratomas. 
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1.3 Benefits of red blood cell manufacture from stem cells 
 
The manufacture of red blood cells from stem cells could potentially overcome the two 
main issues with the current donation system; safety and supply. 
 
1.3.1 Safety 
 
Red blood cells (erythrocytes) are among the simplest cells in the body since they lack a 
nucleus and other membrane-bound organelles [11]. Once matured they are devoid of 
genetic material and can therefore be sterilised using radiation to destroy remnant 
nucleic acids. Irradiation of donated red blood cells is possible (and is usually 
administered to high risk patients) but not practical since it significantly shortens the 
shelf life of an already limited product [12]. Red blood cells manufactured from stem 
cells could be routinely irradiated eradicating the development of TTIs and tumours, 
addressing the current safety issues with red blood cell transfusion.  
 
1.3.2 Supply 
 
Individuals with the O RhD negative (O-) blood group are called ‘universal donors’ 
since their erythrocytes lack detectable antigens and their blood can be given to any 
patient, regardless of blood type. Presently 4% of the eligible UK population donates 
amongst which there is a mixed distribution of blood groups [13]. As can be seen from 
Table 1.1 all donated blood is distributed leading to consistently low stock levels. 
Consequently, this leaves the system vulnerable to shortages, particularly for rare blood 
types. 
The advantage of using erythrocytes manufactured from stem cells is that cells can be 
produced to meet demand, entirely of the O- universal blood type. The cells produced 
would also be a population of entirely ‘new’ cells, so that the shelf life (currently 31 
days) would be increased significantly. 
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Table 3.1 Distributions of blood groups amongst UK donors as of March 2016 
(https://www.blood.co.uk/why-give-blood/the-need-for-blood/blood-groups/ 
accessed June 2016). It is imperative sufficient quantities are collected to meet 
hospital and patient demand 
 
 
 
 
1.4 Competitor products 
 
There have been several outlier replacement products such as perfluorocarbons, 
synthetic haemoglobins and erythropoietic stimulating hormones which have not met 
safety standards owing mainly to problems with biocompatibility [2]. The advantage of 
manufactured red blood cells is that they lack Major Histocompatibility Complexes 
(MHC) and (assuming the correct blood type) there is no risk of immune rejection [6]. 
Since the manufactured red blood cells would be recognised as ‘self’ they would be 
naturally broken down at the end of their 120 day life cycle.  
 
1.5 Types of stem cell 
 
It is possible to derive red blood cells from any of the three main subcategories of 
human stem cells; embryonic (ES), induced pluripotent (iPS) and adult (AS) stem cells. 
Due to differences in source/microenvironment and consequent changes to in vitro 
culture each type of stem cell has its own set of advantages and challenges as shall be 
assessed in the following sections. Some are from a research point of view only as shall 
be specified where appropriate. 
ABO Blood Group Donor population with this group
Blood issued to 
hospitals
A + 30% 30%
A - 8% 8%
B + 8% 8%
B - 2% 2%
O + 36% 36%
O - 12% 13%
AB + 3% 2%
AB - 1% 1%
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1.5.1 Embryonic stem cells 
 
Embryonic stem cells (ES cells) begin with the zygote. Symmetric cell division ensues 
yielding identical daughter cells until the 8 cell stage of the morula (Figure 1.1). At this 
point all cells are totipotent with the ability to give rise to any cell necessary for foetal 
development. 
 
 
 
Figure 1.1; Stepwise differentiation and potency of human embryonic stem cells  
 
The first phase of differentiation begins with the formation of the blastocyst. The outer 
cells of the morula form the outer trophoblast layer which will eventually become the 
placenta and other extraembryonic tissues. The inner cells give rise to the inner cell 
mass (ICM) from which pluripotent ES cells are derived; cells which are able to 
differentiate into any of the three germ layers (mesoderm, endoderm, and ectoderm) 
which comprise the embryo proper [14]. These cells can be manipulated in vitro to 
transit down a desired lineage yielding cells of a particular type, tissue or organ.  
 
1.5.1.1 Advantages: 
 
(a) They are immortal; the first successful culture of a pluripotent and permanent 
human ES line was completed by Thomson et al in 1998 and still exists to this 
day [15]. Hence a desired distinct cell type can be cryopreserved and banked 
indefinitely until needed, eliminating the inconvenience and cost to re-source.  
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(b) They are pluripotent; ES cells are highly susceptible to manipulation in vitro 
since they respond to a wide variety of biochemical cues (Research only)[15]. 
(c) They express low levels of MHC complexes; ES cells have a reduced risk of 
graft rejection which comprises a major issue for allogenic therapies [14]. 
 
1.5.1.2 Disadvantages: 
 
(a) Haematopoietic differentiation of ES cells is a 31 day process requiring germ-
line specification, lineage commitment and maturation though the erythroid 
series. This requires many expensive growth factors such as cytokines and 
increases the risk of error/variation between cultures. 
(b) Blood type specification is not apparent in early stage ES cells and so an 
additional processing step would be required prior to differentiation to identify 
suitable donors (research only)[16]. 
(c) The use of ES cells is controversial.  
 
1.5.2 Induced pluripotent stem cells 
 
Induced pluripotent stem cells (iPS) are adult somatic cells which have been 
reprogrammed to behave like pluripotent ES cells. In 2006, Yamanaka generated the 
first induced pluripotent cell lines by re-programming mouse fibroblasts using four 
transcription factors (Oct3/4, Sox2, Klf4, c-Myc, now known as ‘Yamanaka factors’ 
[17].  Transcription factors control which genes are expressed and thus addition of these 
four particular factors induces artificial transcription of embryonic genes, yielding 
pluripotent stem cells.  
Using this technology cells that are terminally differentiated can be extracted from a 
donor of desired blood type (O-) and induced to artificial embryonic pluripotency before 
directed differentiation to a desired cell type i.e. haematopoietic. Hence although iPS 
maintenance and differentiation is identical to ES cells there are some added benefits to 
their use: 
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1.5.2.1 Advantages: 
 
(a) Immortality 
(b) Pluripotency 
(c) Low expression of MHC complexes  
(d) Can be extracted from a donor of desired blood type 
(e) Their use is not controversial 
 
1.5.2.2 Disadvantages: 
 
(a) Haematopoietic differentiation of iPS cells is a 31 day process 
 
1.5.3 Adult Stem Cells 
 
Adult stem cells (AS) are lineage committed multipotent stem cells which are able to 
develop into more than one cell type within a restricted lineage. They reside in stem cell 
niches in several locales in the adult or juvenile body and  continually repair/ replenish 
organs and tissues, particularly those with a high turn-over (such as blood, skin and 
intestine) or which have been subject to injury [19]. 
 
1.5.3.1 Advantages: 
 
a) They are multipotent; although multipotency could be seen as a drawback 
from a research point of view, a stem cell which has already undergone germ 
layer specification and haematopoietic lineage commitment would be 
beneficial to a bioprocess; by eliminating these early development steps the 
differentiation period is shortened by 10 days reducing reagent and labour 
costs. 
b) They are adult; mature cells express detectable identification markers (for 
example AB+ blood group) so that a potential donor can be carefully selected to 
reduce immune rejection. 
c) The use of AS cells is not controversial 
 
29 
 
1.5.3.2 Disadvantages: 
 
a) They are finite; although AS cells harbour the possibility of becoming immortal 
through genetic manipulation, in their natural state they are finite. Therefore 
their use requires continual resourcing which can be costly and invasive. 
Immortalisation of AS cells requires additional, often time consuming and 
costly, research and development. 
b) They are multipotent; AS cells respond to a smaller pool of biochemical cues so 
that they are not so susceptible to manipulation in vitro.  
 
1.5.4 Cord blood stem cells 
 
CD34+ (haematopoietic stem cell) cord blood stem cells are isolated from umbilical 
cord or placental tissues using immunomagnetic separation. Essentially CBS cells are 
adult stem cells despite their neonatal origin; they have the same aforementioned 
attributes of AS cells although they exhibit some slight morphological and phenotypical 
differences to adult haematopoietic stem cells [19]. Little research has been completed 
on these differences and one of the aims of this research was to ensure that the erythroid 
cells generated were equal to their adult counterparts and hence safe for use in blood 
transfusion. 
 
1.6 Haematopoietic differentiation  
 
Traditionally propagation of ES cells required culture on ‘feeder cells’; mouse or human 
embryonic fibroblasts (MEFs) which secrete diffusible cellular metabolites to 
developing stem cells [9]. The feeder cells were thought to be critical to the growth 
process since some metabolites have short half-lives and need to be secreted 
continuously throughout the culture process [20]. However feeder cells do not have a 
predictable or reproducible secretome which undermines any scientific experimental 
model, particularly in industry where even small differences in culture conditions can 
have a huge impact on the end product. Furthermore, the use of xenogeneic or 
allogeneic sources of feeder cells supports cross-contamination of pathogens and cell 
by-products which could be detrimental to cells and render the end product unusable. 
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Similarly foetal bovine serum (FBS) is often used to supplement cell culture growth 
medium and raises concerns regarding cross-contamination and incorporation of non-
human constituents into the cell environment. Consequently a serum-free feeder-free 
culture system is desirable for the haematopoietic differentiation of ES (and other stem) 
cells. Each of the haematopoietic differentiation protocols used in this research 
(described step-wise in Chapter 2) for ES/iPS and CBS cells were developed by 
Mountford lab, University of Glasgow [unpublished data, personal communication]. 
 
 
 
 
Figure 1.2; Diagram representing the serum-free feeder-free erythroid 
differentiation of ES/iPS cells as orchestrated by the addition of cytokines and 
hormones [21]. For CBS cells the process begins at day 10 since cells are already 
lineage committed. 
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1.6.1 ES and iPS cells 
 
The 31 day haematopoietic differentiation process is initiated with ES/iPS cells grown 
to near confluence in 6 well plates. The cells are cultured in several different 
media/growth factor mixes which direct germ layer specification to mesodermal cells 
and then lineage commitment to haematopoietic progenitor cells. The growth factors 
listed in table 1.2 have been found to reside in haematopoietic stem cell niches and 
where possible their functions are described although some of their mechanisms remain 
elusive. Growth factors is the all-encompassing term for substances necessary for the 
growth and development of cells. Cytokines are small signalling proteins released by 
cells that have specific autocrine or paracrine effects on cellular behaviours. Hormones 
control and regulate the development of cells; their action en vivo is primarily endocrine 
[21].  
 
 
Table 1.2; Function of growth factors used for haematopoietic differentiation 
 
Name Function 
Bone Morphogenetic 
Protein 4  (BMP4) 
Transforming cytokine which induces the expression of 
primitive streak genes which direct development to 
mesodermal and endodermal lineages [22] 
Vascular Endothelial 
Growth Factor (VEGF) 
Cytokine which generates robust Colony Forming Units 
(CFU). Although BMP4 is sufficient to initiate 
haematopoietic gene expression addition of VEGF 
generates 3-4 times more CFU [23] 
Wnt 3A Cytokine which triggers canonical Wnt signalling; as 
intracellular beta-catenin levels rise, beta-catenin binds 
to TCF/LEF transcription factors leading to expression 
of Wnt target genes. Wnt genes have many functions in 
embryogenesis but here they promote self-renewal of 
haematopoietic stem cells [24] 
Activin A Cytokine which inhibits posterior hox genes to suppress 
haematopoiesis momentarily during mesoderm 
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specification. This is to prevent primitive 
haematopoiesis and enable the definitive [25] Activin A 
also promotes mesoderm specification and contributes 
to the expansion of cells already committed to being 
haematopoietic [26] 
GS3K Inhibitor VIII Cytokine which inhibits Glycogen Synthase Kinase 3 
Beta (GSK3b) to enhance Wnt3a activity and improve 
quality of cells post day 24 of the protocol [21] 
Fibroblast Growth Factor 
(FGFα) 
Cytokine which induces differentiation toward 
mesoderm and primes for the haemato-endothelial 
compartment. Increases proliferation more than two-
fold in combination with SCF [21] 
Stem Cell Factor (SCF) Cytokine which binds to and activates the receptor 
tyrosine kinase c-kit which leads to its 
autophosphorylation and signal transduction. It is 
necessary for normal haematopoiesis and proliferation, 
increasing cell yield more than two-fold [27] 
β-Estradiol Hormone which induces differentiation toward 
mesoderm and primes for the haemato-endothelial 
compartment [28] 
Insulin-like Growth Factor 
1&2 
Mitogenic hormones which stimulate proliferation and 
cell survival [29] 
Thrombopoietin (TPO) Glycoprotein hormone which regulates the expansion 
and maturation of megakaryocytes.  It also promotes 
self-renewal of haematopoietic stem cells to establish 
long-term culture initiating cells [30] 
Heparin Anticoagulant which is used to maintain proliferation 
and prevent terminal differentiation [31] 
3-Isobutyl-1-
methylxanthine (IBMX) 
Cytokine which inhibits cGMP phosphodiesterases 
elevating intracellular cAMP levels to activate PKA. 
This results in reduced proliferation but increased 
differentiation [32] 
FMS-like tyrosine kinase 3 Cytokine which binds to tyrosine kinase receptor c-kit 
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ligand (Flt3L) recruiting colony stimulating factors and interleukins to 
induce growth and differentiation [33] 
Interleukins 3 and 11 (IL3 
and IL11) 
Interleukins are cytokines which function in immune 
system signalling. They also support proliferation and 
differentiation of haematopoietic cells IL3 promotes 
proliferation of haematopoietic progenitor cells and 
stimulates differentiation of multipotent haematopoietic 
stem cells into myeloid progenitor cells [34] IL11 is key 
regulator of several stages in haematopoiesis especially 
initiating maturation of megakaryocytes [35,36] 
Erythropoietin (EPO) Hormone which regulates proliferation and 
differentiation of erythroid cells. Upon binding with its 
receptor tyrosine phosphorylation of JAK2 is induced 
which activates an autophosphorylation leading to 
transcription and mitogenesis [37] 
Hydrocortisone Hormone released during the stress response. Increases 
glucose production by gluconeogenesis. 
Immunosuppressant and antidiuretic hormone.  Used to 
stimulate erythroid colony growth and may play a role 
in regulation of erythropoiesis [38] 
Insulin  Hormone which regulates the cellular uptake, 
utilization, and storage of glucose, amino acids, and 
fatty acids and inhibits the breakdown of glycogen, 
protein, and fat [39] 
 
 
1.6.2 CBS cells 
 
CD34 positive CBS cells are grown in suspension culture. The CBS cell haematopoietic 
differentiation requires fewer signalling molecules (as described in Chapter 2) than that 
required for ES/iPS differentiation since the cells are already committed to a 
haematopoietic lineage. 
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1.7 Scale-up to bioreactor culture 
 
At commencement of this research red blood cells were being successfully 
differentiated from ES cells in 6-well plates at Glasgow University (Figure 1.3) A 
typical red blood cell concentrate or unit of blood contains around 2.5 x1012 
erythrocytes [2]. 
 
 
 
Figure 1.3; Red blood cells fabricated from ES cells at Mountford Lab, Glasgow 
03/12/12 day 21 of protocol [personal communication] 
 
ES cells were routinely seeded at 1 x106 cells/well so that the total maximum fold-
expansion would result in 1.92 x1012 erythrocytes, not far off one unit.  However since 
the proliferating cells must be transferred to new plates this culture method is unrealistic 
in terms of space, labour and quality control. In order to transform the haematopoietic 
differentiation protocol into a commercially and clinically viable process it was 
necessary to transfer it to a vessel more amenable to scale-up. 
A 5L (recommended working volume 1.25-3.75L) Celligen BLU Disposable Unit 
Bioreactor (New Brunswick) was purchased for the project with a view to producing 
one unit of blood (Figure 1.4).  
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Figure 1.4; Celligen BLU bioreactor, 
Eppendorf,  http://newbrunswick.eppendorf.com/en/products/bioreactors/ 
25/04/13 
 
Historically stirred tank bioreactors were designed for use with bacterial cells which are 
smaller and inherently more robust. The Celligen BLU bioreactor was designed for use 
with mammalian cells and a trial with HL60 cells at the beginning of the project 
successfully supported 3.4 x106 cells/mL or 1.275 x1010 cells per 3.75 L culture 
(unpublished).  
Stem cells are unique in their en vivo microenvironments and are prone to spontaneous 
differentiation in extraneous conditions. Bioreactors have instrumentation which allows 
the user to harmonise conditions inside the vessel with specific requirements of the cells 
to optimise cell growth, proliferation and ultimately differentiation. Although 
mammalian cell cultures are habitually grown at 37°C, pH 7, 21% oxygen and 5% 
carbon dioxide [40], these parameters are unknown and untested for haematopoietic 
stem cells, warranting further investigation.  
  
 
 
 
36 
 
 
1.8 Considerations for bioreactor culture 
 
1.8.1 Oxygen and stem cells 
 
In order to sustain lifelong cell regeneration, en vivo stem cells must be conserved in an 
environment free from endogenous and exogenous stresses which cause DNA damage. 
Hypoxia is one of the mechanisms by which stem cell niches realise this through 
reduced exposure to reactive oxygen species which induce an oxidative stress response 
leading to dysfunction [41].  
Embryonic [42] and induced pluripotent [43] stem cells which are cultured under 
hypoxic conditions have been shown to upregulate growth factors which maintain the 
pluripotent state to promote self-renewal. Conversely hypoxic culture conditions have 
been shown to induce differentiation and proliferation in several types of multipotent 
(adult) stem cells including neural[44], haematopoietic[45] and mesenchymal[46]. 
These changes are bought about by upregulation of Hypoxia Inducible Factor (HIF-1-
α), a transcriptional regulator for which expression is upregulated at low oxygen 
tensions [43] and induces different responses in stem cells dependent on their level of 
potency/development. 
 Since mesenchymal and haematopoietic stem cell niches have 2-8% and 1-6% oxygen 
concentrations respectively [47] and given that haematopoietic stem cells pass through 
both these phases during their step-wise development, oxygen intensity needs to be 
investigated and carefully controlled at each stage in order to drive proliferation and 
differentiation of desired cell types. 
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1.8.2 Oxygen and red blood cells 
 
Table 1.3; Rate of Oxygen Consumption of Various Types of Cells in Culture [48] 
 
Cell Type 
Rate of Oxygen Consumption (amol cell-1 s-
1) 
Red blood cell (Human) 4 x10-5  
Red blood cell (Rabbit) 2 x10-2  
HL60 with knock out mitochondria 4.7 
HL60 11.5 
Murine macrophages (J774A.1) 31 
Mouse embryonic fibroblasts (MEF) 60 
Baby Hamster Kidney (BHK) 83 
Chinese hamster ovary cells(CHO) 86 
 
 
The oxygen requirement of erythrocytes is markedly low in comparison with other cell 
types (See table 1.3) wherein the vast majority of energy is generated from the Citric 
Acid Cycle, which takes place aerobically in mitochondria (Figure 1.5).  
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Figure 1.5; Fate of glucose entering a cell; cells containing mitochondria harness 
pyruvate produced by glycolysis to generate energy through the aerobic citric acid 
cycle. Cells which lack mitochondria anaerobically convert pyruvate to lactate via 
LDH [49] 
 
Mature red blood cells lack mitochondria (and other membrane bound organelles) 
relying almost entirely on anaerobic glycolysis for ATP production. The pyruvate 
produced by glycolysis is harnessed by lactate dehydrogenase which catalyses its 
conversion into lactate. Effectively around 87.5% of the glucose entering an erythrocyte 
is converted to lactate [50]. 
ES cells do have mitochondria but their immaturity and paucity [51] mean that they 
similarly rely mainly on glycolysis for energy production. Theoretically speaking there 
should be a metabolic shift from glycolysis toward aerobic respiration during 
haematopoietic differentiation consistent with mitochondrial maturation. Since mature 
red blood cells lack mitochondria their eventual omission should mark another 
metabolic conversion from aerobic respiration to glycolysis. Owing to this there should 
be a distinctive optimum oxygen concentration for each stage of 
development/differentiation. 
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Static cell cultures are generally carried out at ambient (21%) oxygen however this can 
cause problems when moving into a stirred tank mammalian cell culture. Sparging is 
required in order to adequately oxygenate the column of media inside the vessel but this 
is highly detrimental to cells (Figure 1.6 [52]).  
 
 
 
 
 
Figure 1.6; Images extracted from Chisti, 2000 [52]. Cells which attach to bubbles 
are destroyed when the bubble disengages with the culture surface creating a fluid 
and submerged jet with a higher energy dissipation than mammalian cells can 
withstand. Smaller bubbles have higher energy dissipation resulting in increased 
death rate 
 
Taking all of these factors into consideration it was hypothesized that lowering the 
oxygen concentration of the differentiation culture would act as a double-edged sword 
by (a) increasing proliferation by hypoxia induced erythropoiesis and/or reduced 
reactive oxygen species and (b) preventing cell death by bubble damage. 
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1.8.3 Oxygen and agitation 
 
Bubbles with smaller diameters reach greater velocities and therefore have higher 
energy dissipation, consequently leading to elevated cell death. These smaller bubbles 
are created by fragmentation during mechanical agitation [52]. 
Agitation or mixing in stirred tank bioreactors is used to ensure homogenous 
distribution of nutrients and other soluble components such as waste products, 
suspended cells and dissolved gases. In this respect a high agitation rate would be 
preferential since it would ensure proper mixing. However there is an upper limit on 
agitation rate since higher speeds cause bubble fragmentation which leads to cell death. 
In order to calculate the most suitable stirrer speed the Reynolds number equation is 
used; 
 
Rei = NiDi2p 
       µ 
 
 in which Ni is stirrer speed, Di is impellor diameter, p is fluid density, µ is fluid 
viscosity. The turbulent regime in stirred tank bioreactors is fully developed when Rei > 
104. Solving this equation should yield a stirrer speed at the boundary of laminar and 
turbulent flow which achieves proper mixing with the least amount of bubble 
fragmentation [40]. 
Gassed liquids have a lower density and therefore require lower stirrer speeds than 
nonaerated fluids. The stirrer speed calculated by the Reynolds equation can therefore 
be reduced by up to 20% for upward-pumping pitched-blade turbines (as used in the 
Celligen BLU Bioreactor)[40]. This calculation of stirrer speed is a crude method and 
requires some further experimentation to find the optimum speed. It was the intention of 
this research to find a more suitable approach to this estimate which would not require 
extensive reagent usage. 
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1.8.4 Agitation rate and shear stress 
 
Shear stress is a tangential force applied to a surface; in bioreactors it is the tangential 
flow of culture media against the surface of cells. Agitation in stirred tank bioreactors 
causes a residual shear stress inside the vessel which does not ordinarily cause cell death 
(without sparging) since it generally remains lower than the cell’s shear threshold. For 
example an agitation rate of up to 100rpm in a Rushton turbine bioreactor results in a 
shear stress of approximately 0.4 N m-2 which lies within the optimum shear range of 
most cell types (0.2-3 N m-2) [53].   
Conversely shear stresses within this range can also cause stem cells to differentiate. 
For example mechanical shear stresses of 1.5 N m-2 have been shown to induce 
mesenchymal stem cells to differentiate into osteoblasts [54] and promote angiogenesis 
in vascular endothelium [55]. Since the optimum shear and its effect on differentiation 
is unknown for haematopoietic stem cells, it was the aim of this research to find the 
optimum shear which would support differentiation of haematopoietic stem cells to 
erythrocytes whilst promoting cell proliferation.  
 
1.8.5 pH and Stem Cells 
 
Traditionally animal cells are cultured in incubators which maintain CO2 at 5%, which 
in turn maintains the pH of the growth medium at 7.4 [40]. However cell yield and 
development may be optimised by adjusting the pH.  
For example one study found that the optimum pH for murine embryoid bodies was 
7.3, not only in cell yield but in producing the correct cell types. A pH which deviated 
from this optimum by only 0.15 resulted in suboptimal cultures which did not 
comprise cells of all 3 germ layers [56][57]. Hence finding the correct pH prior to 
differentiation is paramount to ensure the correct cell types are present. 
Furthermore, the optimum pH range for differentiating human erythroid cells was 
found to be between 7.5 and 7.6 which not only induced higher production of 
haemoglobin in erythroid cells but also may have acted as a trigger for differentiation 
[58] 
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Since little research has been completed in this field effects of carbon dioxide and pH 
on stem cell culture and differentiation need to be examined and optimised for each 
stage of development. 
 
During this research the intention was to investigate the effects of oxygen, carbon 
dioxide/pH and shear stress on differentiating haematopoietic stem cells. Due to time 
constraints alteration of CO2/pH levels and any corresponding effects were not 
assessed and these parameters will need to be investigated in the future. 
 
1.8.6 Red Blood Cells and Platelet Aggregation 
 
En vivo platelet aggregation occurs only when subendothelial collagen is exposed by 
blood vessel damage [59]. This coupled with Von Willebrand factor, which is released 
at the site of injury, recruits platelets to the exposed site. Upon this interaction integrin 
receptors on platelet walls are activated and bind to the collagen. Once bound the 
platelet/s release adenosine triphosphate (ADP) causing a procoagulant conformational 
change which aids further binding and recruitment of platelets to form aggregates [59]. 
Hence red blood cells are not ordinarily involved in platelet aggregation but they do 
contain ADP which is released following membrane damage to induce the procoagulant 
shape change [59].  
To date there are no known mechanisms by which red blood cells are able to repair 
membrane damage since they lack a nucleus. However this seems counter-intuitive 
since the heme and haemoglobin released by such damage could cause acute kidney 
injury [60]. 
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1.9 Ultra-scale down – Microfluidics 
 
Although the aim of this research was to scale-up the haematopoietic differentiation 
protocol to a 5L bioreactor the cost of reagents and the unknown effects of the physical 
bioreactor environment render it an expensive and high risk operation. An ultra-scale 
down method was proposed by which the optimum parameter conditions could be tested 
prior to use of the Celligen BLU Bioreactor. 
 
Human cells and capillaries are generally in the range 5-30 µm which renders 
microfluidics an appealing mode of cell biology study from a practical point of view; 
more physiologic cell volume to extracellular fluid ratios (usually >1) are attainable 
which are more representative of  en vivo conditions and hence yield more realistic 
results [61].  
Micro-scaling of physical forces is also advantageous. Although the laws of physics 
remain the same as in a macroscopic system, frictional forces become predominant over 
inertial forces leading to formation of laminar flows. Particles in laminar regimes flow 
parallel to one another forming streamlines as opposed to turbulent flow in macroscale 
systems (Figure 1.7) [40].  
 
This is highly advantageous since flows in microfluidic devices can be modelled and 
tightly controlled [62] particularly in reference to stem cells and their differentiating 
counterparts which are sensitive to even the slightest fluctuations in their physical 
environment [41-45]. Furthermore the laminar perfusion system can be used to 
implement biosensors before and after the culture chamber so that utilization of 
molecules of interest can be accurately monitored throughout the culture period.   
The small scale microfluidic system can be subjected to a spectrum of conditions and 
easily integrated into a monitoring system such as microscopic imaging [62]. It was the 
intention of this research to use microfluidic devices in conjunction with fluorescent 
biosensors for in-situ imaging and quantification of cellular metabolites.  
 
Crucially low reagent usage and reusable devices can decrease experimentation costs. 
Although miniature (for example Ambr, TAP Biosytems) bioreactors are available 
these are expensive, the reagent usage is much higher, the environment is not so 
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carefully modelled/defined and they cannot easily be used in conjunction with 
biosensors [63].   
The estimated cost to run a haematopoietic differentiation culture in the Celligen BLU 
Bioreactor purchased for the use on the project is >£5000. Hence an ultra-scale down to 
microfluidic proportions was favourable for the initial stages of this research until the 
suitable physical environment of the differentiating culture is known. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45 
 
1.10 Microfabrication techniques 
 
1.10.1 Polydimethylsiloxane devices using soft-lithography 
 
Polydimethylsiloxane (PDMS) is the most common material used for the fabrication of 
microfluidic devices since it is inexpensive, non-cytotoxic, autoclavable and gas 
permeable to allow for cell respiration. Devices are usually fabricated using soft-
lithography whereby a mould is prior-made using photolithography (Figure 1.7a-c) and 
then the PDMS is applied and cured to obtain the device (d-f)[64].  
 
 
 
 
Figure 1.8 [64]; Steps a-c show the process for photolithography, steps d-f show 
soft-lithography. (a) SU-8 photoresist is spin-coated onto a silicon wafer (b) a 
transparency or ‘photoresist’ mask is aligned and UV light applied (c) the exposed 
regions are polymerised by UV light (negative photoresist) and following 
submersion in developing solution the unexposed areas are dissolved (d) PDMS is 
poured onto the SU-8/silicon mould (e) The PDMS is cured and peeled away from 
the mould (f) the PDMS device is punched with inlets, outlets and applied to a 
substrate 
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The disadvantage of this method is that the photolithography steps require specialist 
training, equipment and access to a clean room. Often fabrication of photolithography 
moulds is outsourced to a dedicated company which can be time-consuming, expensive 
and the geometries are finite. Since it was perceived that the microfluidic device would 
take some development this was not considered a viable option for the purposes of this 
research. 
 
1.10.2 Silicone devices using photolithography 
 
This fabrication method uses Ultraviolet (UV) light to transfer a geometric pattern from 
a photomask onto a light-sensitive chemical photoresist. The ‘photomask’ is the 
microchannel geometry patterned onto a chromium-lined glass or quartz plate. The 
photo-resist material (often SU-8) is a viscous fluid which is spin-coated onto a silicon 
wafer and then hardened by baking. The two are aligned and exposed to UV light. 
Depending on whether a negative or positive photoresist is used the exposed area is 
removed or preserved during submersion in development fluid. The device can then be 
bonded to a substrate of choice [65]. 
As mentioned previously, photolithography was not considered suitable for this project 
mainly due to restrictions on channel geometry. 
 
1.10.3 Silicone devices using femtosecond laser writing 
 
Microchannel geometries are etched into the interiors of silicon wafers (and other 
transparent materials) using a femtosecond laser. The etched material is then dissolved 
in a weak acid to expose the channel. The advantages of this method are that it creates a 
closed channel system less prone to leaks and contamination, has the potential for 
complex circuits and is cost effective [66]. Silicone was considered an ideal substrate 
for the device since it is clear, gas impermeable, non-cytotoxic and can be sterilised by 
autoclave [67]. Initially devices were fabricated using this method however it was 
considered too restrictive in terms of time, size and adaptability.  
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1.10.4 Poly (methyl methacrylate) devices using laser cutting 
 
Laser cutting can be used to cut or etch into a number of different materials. Poly 
(methyl methacrylate) PMMA is particularly useful for microdevices since it is 
transparent, non-cytotoxic and inexpensive [68]. Usually the device is constructed of 3 
or more layers (base, channels, and lid) which are then aligned and bonded permanently 
using heat/sealant or temporarily using gaskets [69]. This method was used primarily 
for the development of the device since it is inexpensive and fast allowing for several 
geometries to be trialled before deciding on a final design. The disadvantage of this 
method is that PMMA cannot be sterilized by autoclaving which leaves the system 
vulnerable to contaminations.  
 
1.10.5 Other Polymers 
Due to the high volume of laboratory and manufacturing work required for the project 
other methods of fabrication were not suitably researched at the time. Other 
autoclavable polymers (such as cyclic olefin copolymer (COC) and polycarbonate (PC)) 
were considered briefly, however hot embossing is required for fabrication [69]. Since 
no autoclavable polymers could be found which were amenable to the fabrication 
methods used/available it was felt that too much time would be required for 
development and they were dismissed in favour of other autoclavable materials such as 
glass and steel which could be machined on-site. 
 
1.10.6 Glass and stainless steel devices by machining 
 
Microfluidic devices can be fabricated using traditional machining methods such as 
milling, turning and drilling. As will be explained in Chapter 3 a second larger device 
was fabricated using this method. Machining was also used to add supplementary 
features to PMMA devices. 
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1.11 Microfluidic biosensors 
 
1.11.1 Oxygen sensors 
The classical oxygen sensor is the Clark electrode sensor which works by detecting 
current flow caused by reduction of oxygen [64]. The miniaturisation of these sensors to 
feature in microfluidic devices requires the use of microscale electrodes which consume 
oxygen intended for quantification. They also require electrical connection difficult to 
integrate on a microfluidic device and can render it susceptible to contamination. 
Optical oxygen sensors are a far less intrusive form of sensor, easily integrated into a 
microfluidic platform and do not consume oxygen. Most operate on the principle of 
reversible luminescence quenching by oxygen [65]. 
 
The most widely used sensors for luminescent quantification and detection of oxygen 
are Ruthenium based probes. Their high luminescence, photo stability, biocompatibility 
and ease of integration into microfluidic devices through polymer encapsulation make 
them ideal candidates for oxygen detection in microfluidic devices [65] ruthenium-
tris(4,7-disphenyl-1, 10-phenanthroline) dichloride Ru(dpp) complex is dissolved in 
ethanol and mixed with PDMS polymer base and curing agent [70] the mixture can then 
be applied to a microfluidic sensing chip.  
 
 
 
Figure 1.9; Fluorescence (left) and brightfield (right) images of oxygen ruthenium 
biosensor microtrenches [70] 
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The fluorescence of the ruthenium complex is efficiently and reversibly reduced by 
molecular oxygen due to dynamic quenching [64] The decrease in fluorescence 
intensity is then measurable using standard fluorescence microscopy setups and the 
Stern-Volmer Equation; 
 
 
 
 
 
Where I is the fluorescence in the presence of the quencher (oxygen), Io is the 
fluorescence in the absence of the quencher and k is the Stern-Volmer constant. Plots of 
 
I/Io can then be used to determine changes in oxygen concentration [71]. Although 
these biosensors were developed commercially over the duration of this research, the 
novel application was in their implementation in a novel microfluidic device which 
could be used to measure in-situ oxygen consumption rates of differentiating stem cells. 
 
1.11.2 Glucose sensors  
It was hoped that the microfluidic sensing chip would also implement a glucose sensor 
since it is the chief source of energy for cells, particularly red blood cells. Optical 
glucose sensors work based on the activity of the carbohydrate-binding protein (lectin) 
Concanavalin A (ConA) which has high affinity for glycoconjugates [70]. Change in 
glucose concentration is detected through fluorescence resonance energy transfer 
(FRET) between fluorescein isothiocyanate (FITC)-bound dextran and ConA 
tetramethylrhodamine (TR) conjugate. In the absence of glucose FITC-bound dextran is 
bound to ConA-TR conjugate and FITC fluorescence is quenched through FRET. When 
glucose concentration increases it competes with the FITC-bound dextran displacing it 
and FITC fluorescence is detectable in proportion to glucose concentration [70]. These 
fluorescent probes can be similarly integrated into microfluidic chips by immobilisation 
with PDMS and quantified using fluorescence microscopy. Although a glucose 
50 
 
biosensor was successfully fabricated it was not compatible with sterilisation methods 
necessary for the microdevice and requires further development. 
1.11.3 Carbon dioxide/pH and lactate sensors 
It was the intention at the beginning of this research to develop optical CO2 and lactate 
sensors however these were unsuccessful. Presently there are no such sensors which are 
amenable to integration into a microfluidic system.  
1.12 Offline analysis 
1.12.1 Flow cytometry 
Flow cytometry is the simultaneous measurement of a range of characteristics of cells 
that pass in single file (in suspension) past one or more lasers. Each ‘event’ created as 
one cell passes the laser gives information about its size and complexity. Additionally 
the cells can be labelled with fluorescence to identify desirable traits. The advantage of 
using flow cytometry as an analysis method is that samples are quick and easy to 
prepare and data for an entire cellular population is collected quickly [72]. There are 
also a wide range of fluorescence probes available for rapid identification of a myriad of 
cellular features and processes as shall be discussed in the following sections. 
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Figure 1.10; Process of flow cytometry. First cells are labelled with fluorescent 
probes then the cell suspension enters the flow cell and as each cell passes the 
lasers an ‘event’ is created which gives information about the fluorescent 
properties of the cell. Information on cell size and complexity are collected using 
transmitted light. Images taken from BD Biosciences 29/06/16 
 
 
 
 
52 
 
1.12.2 Cell surface markers 
Cells have a unique combination of surface markers which are often transient in nature 
and can be used to identify key points in haematopoietic differentiation. A marker 
profile was developed at Mountford Laboratories, University of Glasgow [personal 
communication, unpublished data] and adopted at Heriot Watt University as part of the 
differentiation process transfer. Table 1.4 shows the markers and the cell types they are 
used to identify throughout the protocol. SSEA3, SSEA4 and TRA-160 markers are 
usually only found on ES cells and can therefore be used to gauge pluripotency of a 
population. Following differentiation they are downregulated.  
 
Table 1.4; Cell Surface Markers and their identifying cell type 
 
Name Cell Type 
SSEA3 Pluripotent 
SSEA4 Pluripotent 
TRA-160 Pluripotent 
CD34 Haematopoietic stem cell 
CD45 Leukocyte common antigen 
CD31 Haemangioblast 
CD43 Haemangioblast 
CD235a Haemangioblast and erythrocyte 
CD71 Transferrin receptor on erythroid cells 
CD36 Early erythroid 
CD41a Haemangioblast and platelets 
CD42b Platelets 
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Figure 1.11; Analysis of CD markers on differentiating ES cells as obtained using 
flow cytometry at Mountford Laboratories University of Glasgow[21] Since CBS 
cells are already lineage committed their marker profile should start at day 10. 
The same panel was used for analysis at Heriot Watt although without CD133 
Haemangioblastic markers CD34, CD31, CD43 and CD41a mark a transient stage of 
multipotency whereby cells have the potential to become haematopoietic or endothelial. 
Following this they undergo further lineage commitment to early erythroid as indicated 
by CD36 (although there is a short transient peak in leukocyte marker CD45). The late 
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erythroid markers CD235a and CD71 should then remain elevated if the differentiation 
is successful [21]. Although CD41a is known to be a haemangioblast marker it is more 
commonly known as a marker for platelets and megakaryocytes. In order to confirm 
platelet presence in parts of this research CD42b was added to the panel.  
1.12.3 Apoptosis/Necrosis 
There are two kinds of cell death. Apoptosis is a programmed, autonomous dismantling 
of the cell and its components whilst necrosis describes accidental cell death caused by 
unexpected trauma. During apoptosis phosphatidylserine (PS) is transferred from the 
inside of the plasma membrane to the outer leaflet due to phospholipid flipping [73]. 
Necrotic cells exhibit inflammation and loss of plasma integrity since this type of cell 
death is unplanned [74].  
 
 
Figure 1.12; Morphologic differences observed for the two types of cell death, 
necrosis (left) and apoptosis (right) 
[http://medicinembbs.blogspot.co.uk/2011/03/programmed-cell-death-
apoptosis.html June 2016] 
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Although morphologic differences should be visible under a microscope (Figure 1.10) 
an entire population can be more easily and accurately analysed by flow cytometry. 
Apoptosis is detected using a fluorescent probe specific to exposed PS on the cell 
surface whilst a membrane impermeable dye is used to detect necrosis as it diffuses 
through the degraded cell walls of necrotic cells (Abcam).  These stained cell 
populations are then sampled for flow cytometry analysis.  
1.12.4 Mitochondria 
Mitochondria are double membraned organelles. The outer membrane has larger pores 
which allows for passage of ions and small molecules. The inner membrane surrounding 
the mitochondrial matrix is much more selective and is studded with proteins involved 
in electron transport and ATP synthesis as shown in Figure 1.11 [75]. 
 
 
 
Figure 1.13; Mitochondrial double membrane which surrounds the mitochondrial 
matrix where the aerobic citric acid cycle takes 
place. http://www.nature.com/scitable/topicpage/mitochondria-14053590, 15/06/16 
 
The intermembrane space has a high concentration of hydrogen ions which creates a 
proton gradient. Mitochondria can be stained with fluorescent probes which accumulate 
in live mitochondria via this potential gradient. Once stained the mitochondria can be 
analysed using flow cytometry or fluorescence microscopy. 
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1.12.5 Hypoxia inducible factor subunit 1-alpha 
Hypoxia Inducible Factor 1 alpha (HIF-1-α) is a subunit of a master regulator of cellular 
responses to hypoxia, HIF-1 [76].  It induces the transcriptional activation of many 
genes involved in energy metabolism, erythropoiesis, apoptosis and several other 
responsive adaptations. Hif-1drives expression of glycolytic genes since glycolysis is 
necessary to produce energy when oxygen is low. It is also represses mitochondrial 
function by inducing pyruvate dehydrogenase kinase 1 (PDK1) which phosphorylates 
and inhibits pyruvate dehydrogenase from using pyruvate to fuel the mitochondrial 
TCA cycle [77].  Hence upregulation of HIF-1-a is considered to be a marker of cellular 
response to hypoxia.  HIF-1-α can be labelled with fluorescent probes and assessed 
using techniques such as Western blot and immunochemistry. 
1.12.6 Reactive oxygen species 
Reactive Oxygen Species (ROS) are a natural by-product of cellular metabolism. It is 
believed that stem cell niches are hypoxic in order to protect from oxidative stress 
inflicted by ROS [77]. Cytoplasmic ROS can be labelled with fluorescent probes for 
visualisation by microscopy and/or flow cytometry. 
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Chapter 2 – Materials and Methods 
 
2.1 Cell lines 
 
2.1.1 RC9b human embryonic stem cells 
 
The RC9 cell line was purchased from Roslin Cells and renamed RC9b to distinguish 
new banks which were created at Glasgow/Heriot Watt Universities. They are clinical 
grade pluripotent human embryonic stem cells (hESC) derived from B+ blastocysts. 
Since embryonic stem cells are in a state of self-renewal they are immortal and can be 
passaged continuously. However their pluripotency depreciates with each passage due 
to spontaneous differentiation and cultures were therefore routinely discarded at Passage 
38 based on pluripotency markers and karyotype analysis. 
 
2.1.2 SFC i55 human induced pluripotent stem cells 
 
Human induced pluripotent stem cells (iPS) were produced from dermal fibroblast cell 
lines generated from donors with an O negative blood group. The fibroblasts were 
reprogrammed using Oct 4, Sox 2, c-Myc and Klf 4 transcription factors to produce 
pluripotent stem cells. The resultant cells were then screened for pluripotency markers 
(TRA1-60, OCT4, SSEA-4 and lack of expression of early differentiation marker 
SSEA-1), ability to differentiate into blood cells and single-nucleotide polymorphism 
(SNP) analysis/karyotyping to ensure cell line stability. The most reliable cell line 
produced was SFC i55 which was then expanded for further laboratory use. Since iPS 
cells mimic hESCs they were maintained and discarded in the same manner. 
 
2.1.3 Human CD34+ Cord Blood Stem Cells 
 
Primary human CD34+ cells are haematopoietic progenitors and were purchased from 
Stemcell Technologies Incorporated. The cells were isolated from umbilical cord blood 
using positive immunomagnetic separation from mothers who tested negative for HIV-
58 
 
1, HIV-2 and Hepatitis B. Hepatitis C tests were completed at time of collection. Cord 
blood cells are finite and had to be continuously resourced. 
 
2.2 Model cell lines 
 
Haematopoietic differentiation of the aforementioned stem cells involves both adherent 
and suspension stages and their development is directed by the use of expensive 
cytokines/growth factors. Since it was anticipated this research would entail augmented 
reagent usage, two haemocytic model lines were selected for preliminary 
experimentation based upon robustness, cost efficiency and simplicity of 
culture/maintenance. They also share similar characteristics such as size, shape and 
elasticity. 
 
2.2.1 Haemocytic suspension cells; HL60  
 
HL60 leukocytes were first derived from the peripheral blood of a 36 year old female 
patient with acute promyelocytic leukaemia in 1977. They are haemocytic suspension 
cells which are supplemented with serum so that they do not require expensive growth 
factors and they are immortal which makes them an ideal model cell line for preliminary 
scale-up experiments. 
 
2.2.2 Haemocytic adherent cells; J774  
 
The J774 monocyte macrophage cell line was first isolated in 1968 from sarcoma cells 
of the murine reticulum. J774s are haemocytic adherent cells which serum 
supplemented so that they do not require expensive growth factors and are immortal, 
making them an ideal cell line for mimicking the adherent stages of haematopoietic 
stem cells. Both J774 and HL60 cell lines were purchased from Sigma Aldrich for use 
on this project. 
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2.3 Aseptic technique 
 
Stem cells (and their model equivalents) must be cultured without the use of antibiotics 
and therefore a high standard of aseptic technique was applied to all applications. Cell 
cultures were carried out in a class II laminar hood which was designated exclusively 
for stem cell use and wiped down prior and post culture with Distel followed by 70% 
ethanol. All plastics and tools were pre-sterilised and sprayed with 70% ethanol prior to 
introduction to the hood. Many of the experiments carried out during this research took 
place in non-sterile environments. In these instances all equipment was routinely 
cleaned by sonication and sterilised by autoclave and/or UV radiation. Inoculation took 
place in a sterile hood and sterile connections made before the removal and integration 
into the experimental apparatus.  
 
2.4 Cell culture protocols 
 
2.4.1 Stem cell maintenance 
 
Since cord blood cells are finite and continuously resourced maintenance was required 
for RC9b and SFC i55 cells only. First subculture post-defrost cells were split 1:3 with 
subsequent subcultures split 1:6. Cells were always subcultured again within 10 days of 
defrost to prevent spontaneous differentiation. 
 
1) Coating 6 well plates: 
Costar 3516 6 well plates were coated with 1mL of Stem Cell Technologies Vitronectin 
XF at a final concentration of 10µg/mL. Stock vitronectin (250 µg/mL) was removed 
from -80 °C freezer and defrosted to room temperature. In a polypropylene tube 40 µL 
of stock vitronectin was added to 960 µL Dulbecco’s PBS (Ca2+/Mg2+ free) for each 
well and mixed by pipetting. The diluted vitronectin was added 1mL per well and the 
plate sealed with Parafilm® to prevent evaporation. The plate was then shaken on a 
rocking platform at room temperature for >1 hour to ensure an even coating. Following 
this the excess vitronectin was aspirated to waste and each coated well washed with 
2mL Dulbecco’s PBS (Ca2+/Mg2+ free). 
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2) Preparation of culture media: 
The required volume of StemPro® Complete medium (ThermoFisher) was prepared 
according to Table 2.1 and pre-warmed to 37 °C 
 
 
Table 4.1; StemPro® hESC SFM Complete Medium 
 
 Final 
Conc 
For 15 mL For 10 mL For 5 mL 
DMEM/F12 + 
GlutaMAX (1X) 
1X 13.56 mL 9.04 mL 4.52 mL 
StemPro® hESC SFM 
growth supplement 
(50X) 
1X 0.3 mL 0.2 mL 0.1 mL 
BSA 25% 1.8% 1.08 mL 720 µL 360 µL 
FGF-basic (20 µg/mL) 20 ng/mL 15 µL 10 µL 5 µL 
2-mercaptoethanol      
(50 mM) 
0.1 mM 30 µL 
 
20 µL  10µL 
 
 
3) Subculturing cells: 
Cells to be subcultured had their media changed 1-2 h prior to passage using 3 mL of 
pre-warmed StemPro® Complete growth medium per well. A StemPro® EZPassage™ 
tool (ThermoFisher) was used to cut the stem cell monolayer three times top to bottom 
and three times left to right across the well. The ‘squares’ of cells were then collected 
using a 5 mL pipette, pipetting up and down over the centre of the well to ensure all cell 
squares were aspirated. The cell suspension was used to seed directly into prepared 
vitronectin coated plates e.g. for a 1:6 subculture 0.5 mL of the cell suspension was 
placed into each of the 6 wells. StemPro® Complete medium was added to each well to 
ensure a total volume of 2 mL/well. Plates were gently rotated by hand left to right and 
up /down to ensure the cells were evenly spread across the seeded wells. Plates were 
placed in an incubator at 37 °C 5% CO2 and media changed daily until next 
passage/subculture. 
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2.4.2 Haematopoietic differentiation of RC9b/SFC i55 
 
2.4.2.1 Day 0 cell counting  
 
Wells of RC9b/SFC i55 which had grown to 80-85% confluent were used as starting 
material.  
Prior to initiation of the protocol one well was sacrificed for cell counting. Cell culture 
media was aspirated to waste and the cell monolayer washed with Dulbecco’s PBS 
(Ca2+/Mg2+ free). 1mL TrypLE™ Select, a recombinant cell-dissociation enzyme, 
(ThermoFisher), was added to the well and the cells were incubated for 10 minutes at 37 
°C. Following this, cells were removed from incubator and fully dissociated by 
pipetting up/down with a 5mL pipette. Once dissociated the cells were added to a 15mL 
centrifuge tube and washed with 14mL Dulbecco’s PBS (Ca2+/Mg2+ free). The cells 
were centrifuged at 1200rpm for 3 minutes and supernatant removed before 
resuspending in 1mL Dulbecco’s PBS (Ca2+/Mg2+ free).  A cell sample was then 
counted on a haemocytometer using the trypan blue exclusion method. 
 
2.4.2.2 Trypan blue exclusion method 
 
The trypan blue exclusion method is based on the principle that viable cells have intact 
membranes which exclude specialized dyes including trypan blue. Only cells which are 
dead (with impaired membranes) are able to absorb the dye and are therefore easily 
distinguished from viable cells. 
A small sample of cell suspension (usually 20µL) was diluted 1:1 with trypan blue in a 
microcentrifuge tube or bijou and mixed by pipetting up and down. Cells were then 
loaded into haemocytomer chambers and counted at x10 magnification using a Nikon 
microscope. In order to calculate cell density the number of cells counted was 
multiplied by the dilution factor and 104 to determine number of cells in 1mL. For 
example if 73 cells were counted in total then; 
 
73 x 2 x 104 = 1.46 x106 cells/mL. 
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Cells which were deep blue in colour were considered dead and excluded in the 
following equation to calculate cell viability; 
�
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑛𝑛𝑇𝑇. 𝑇𝑇𝑜𝑜 𝑐𝑐𝑐𝑐𝑇𝑇𝑇𝑇𝑐𝑐 −  𝑛𝑛𝑇𝑇. 𝑇𝑇𝑜𝑜 𝑏𝑏𝑇𝑇𝑏𝑏𝑐𝑐 𝑐𝑐𝑐𝑐𝑇𝑇𝑇𝑇𝑐𝑐
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑛𝑛𝑇𝑇. 𝑇𝑇𝑜𝑜 𝑐𝑐𝑐𝑐𝑇𝑇𝑇𝑇𝑐𝑐 � × 100 = 𝐶𝐶𝑐𝑐𝑇𝑇𝑇𝑇 𝑣𝑣𝑣𝑣𝑇𝑇𝑏𝑏𝑣𝑣𝑇𝑇𝑣𝑣𝑇𝑇𝑣𝑣 
For example if 2 of the 73 cells were deep blue/dead then; 
�
73 − 273 � 𝑥𝑥100 = 𝐶𝐶𝑐𝑐𝑇𝑇𝑇𝑇𝑐𝑐 𝑇𝑇𝑎𝑎𝑐𝑐 97.3% 𝑣𝑣𝑣𝑣𝑇𝑇𝑏𝑏𝑇𝑇𝑐𝑐 
 
 
2.4.2.3 Differentiation 
 
Following cell counting media was removed from remaining wells and aspirated to 
waste with care not to disturb the stem cell monolayers. The cells were washed in 
Dulbecco’s PBS (Ca2+/Mg2+ free) by adding 3mL to each well and leaving for 1 minute 
before aspirating to waste. 3mL/well Stemline® II medium (Sigma Aldrich) 
supplemented with cytokines and small molecules as shown in Table 2.2 (below) was 
added to each well. Using a StemPro® EZPassage tool cells were cut into rough squares 
by cutting three times top to bottom and three times left to right across the well. The cell 
‘squares’ were then dissociated from wells by pipetting up/down with a 5mL pipette. 
Cells were pooled in a 15mL centrifuge tube before addition to a Costar Ultra-low 
Attachment 6 well plate at 1.5 x106 cells per well. Additional media/cytokine mix was 
added to a final volume of 3mL per well.  
 
Table 2.2; Day 0 Cytokine mix 
 
Factor [Final] [Stock] 1ml (1x) 3ml (1x) 6ml (1x) 12ml(1x) 
BMP4 10ng/mL 50ng/µL 0.2µL 0.6µL 1.2µL 2.4µL 
VEGF 10ng/mL 50ng/µL 0.2µL 0.6µL 1.2µL 2.4µL 
Wnt3A 10ng/mL 10ng/µL 1.0µL 3.0µL 6.0µL 12µL 
Activin A 5ng/mL 10ng/µL 0.5µL 1.5µL 3.0µL 6.0µL 
Inhibitor 
VIII 
2µM 2mM 1.0µL 3.0µL 6.0µL 12µL 
 
 
63 
 
2.4.2.4 Day 2  
 
By day 2 the cells had formed embryoid bodies (three-dimensional aggregates of 
pluripotent stem cells) and were now tubular/rounded in shape rather than square. At 
this stage 0.5mL Stemline® II media was added per well with a x6 concentration of 
cytokines as shown in Table 2.3. This assumes a loss of 0.5mL media through 
evaporation to bring the final volume back to 3mL. 
 
Table 2.3; Day 2 Cytokine Mix 
 
Factor [Final] [Stock] 1ml(1x) 1ml(6x) 2ml(6x) 
BMP4 20ng/mL 50ng/µL 0.4µL 2.4µL 4.8µL 
VEGF 30ng/mL 50ng/µL 0.6µL 3.6µL 7.2µL 
Inhibitor 
VIII 
2µM 2mM 1.0µL 6.0µL 12.0µL 
Wnt3A 10ng/mL 10ng/µL 1.0µL 6.0µL 12.0µL 
Activin A 5ng/mL 10ng/µL 0.5µL 3.0µL 6.0µL 
FGFα 10ng/mL 50ng/µL 0.2µL 1.2µL 2.4µL 
SCF 20ng/mL 50ng/µL 0.4µL 2.4µL 4.8µL 
β-Estradiol 0.4ng/mL 0.4ng/µL 1.0µL 6.0µL 12.0µL 
 
2.4.2.5 Day 3 
 
At day 3 the embryoid bodies were harvested from the wells and pooled into a 15mL 
centrifuge tube. The cells were centrifuged at 100g for 1 minute and the supernatant 
aspirated to waste. 1mL TrypLE® Select was added and cells mechanically dissociated 
by pipetting up and down gently. The cells were then transferred to an empty well of a 6 
well plate and incubated at 37oC for 10min occasionally pipetting up and down to aid 
dissociation. After 10min the dissociated cells were placed in a 15mL centrifuge tube 
with 14mL of Dulbecco’s PBS (Ca2+/Mg2+ free) and centrifuged for 3min at 310g. The 
supernatant was aspirated to waste and the cell pellet resuspended in 6mL fresh 
Dulbecco’s PBS (Ca2+/Mg2+ free). The cells were centrifuged again for 3 minutes at 
310g and the supernatant aspirated. The cells were resuspended in 4 mL- Stemline® II 
with cytokines (Table 2.4) and a 10 µL sample counted on a haemocytometer using the 
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trypan blue exclusion method. Cells were then seeded at 200,000/well in Stemline® II 
with cytokines (Table 2.4) in Costar 3516 6 well plates. 
 
Table 2.4; Days 3-9 Cytokine mix 
 
Factor [Final] [Stock] 1mL(1x) 1mL(6x) 2mL(6x) 
BMP4 20ng/mL 50ng/µL 0.4µL 2.4µL 4.8µL 
VEGF 30ng/mL 50ng/µL 0.6µL 3.6µL 7.2µL 
FGFα 10ng/mL 50ng/µL 0.2µL 1.2µL 2.4µL 
SCF 30ng/mL 50ng/µL 0.6µL 3.6µL 7.2µL 
IGF2 10ng/mL 50ng/µL 0.2µL 1.2µL 2.4µL 
TPO 10ng/mL 50ng/µL 0.2µL 1.2µL 2.4µL 
Heparin 5µg/mL 5mg/mL 1µL 6µL 12µL 
β-Estradiol 0.4ng/mL 0.4ng/µL 1.0µL 6.0µL 12.0µL 
IBMX 50µM 100mM 0.5µL 3.0µL 6.0µL 
 
 
2.4.2.6 Day 5 
 
By this stage cells had become adherent with possible signs of budding. Fresh cytokines 
were added 0.5mL of x6 concentration cytokines/well as per table 2.4.  
 
2.4.2.7 Day 7 
 
A complete media change was required at this stage. Cells were harvested from wells 
and pooled into a centrifuge tube before centrifuging for 3min at 310g. Any adherent 
cells were left in the wells and 1mL fresh media/cytokine mix (Table 2.4) added. 
Supernatant from sedimented cells was discarded and cells resuspended in fresh 
media/cytokine mix (3ml/well final volume) according to table 2.4 but with half the 
dose (2.5µg/mL) heparin.  
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2.4.2.8 Day 9 
 
Fresh cytokines were added x3 concentration (since only one day until media change) in 
0.5ml Stemline® II media per well according to Table 2.4.  
 
 
2.4.2.9 Days 10-17 
 
By this stage cells were rapidly proliferating red suspension cells with very little 
budding (if any) remaining. Cells were harvested and pooled into a 15mL centrifuge 
tube then centrifuged at 310g for 3 minutes. The supernatant was discarded and the cells 
resuspended in 3mL/well Stemline® II with cytokines according to Table 2.5. The cells 
were supplemented every second day with 0.5mL Stemline® II with x6 concentration of 
cytokines. 
 
Table 2.5; Days 10-17 Cytokine Mix 
 
 
 
 
 
 
 
 
2.4.2.10 Days 17-24 
 
Cells were counted using the trypan blue exclusion method before harvesting into a 
centrifuge tube and centrifuging at 310g for 3 minutes. The supernatant was discarded 
and cells washed in Dulbecco’s PBS (Ca2+/Mg2+ free) before resuspending in IBIT 
media (Table 2.6) supplemented with cytokine mix C (Table 2.7). Cell were seeded at 
Factor [Final] [Stock] 1mL(1x) 1mL(6x) 2mL(6x) 
Hydrocortisone 1µM 1mM 1µL 6.0µL 12.0µL 
SCF 50ng/mL 50ng/µL 1.0µL 6.0µL 12.0µL 
Flt3L 16.7ng/mL 50ng/µL 0.33µL 2.0µL 4.0µL 
BMP4 6.7ng/mL 50ng/µL 0.134µL 0.8µL 1.6µL 
IL3 6.7ng/mL 50ng/µL 0.134µL 0.8µL 1.6µL 
IL11 6.7ng/mL 50ng/µL 0.134µL 0.8µL 1.6µL 
EPO 3U/mL 10U/µL 0.3µL 1.8µL 3.6µL 
IBMX 50µM 100mM 0.5µL 3.0µL 6.0µL 
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1x106 cells/well in Costar 3516 6 well plates. Cells were supplemented every 2 days 
with 0.5mL IBIT supplemented with 6x concentration cytokine mix C. 
 
IBIT 
 
Table 2.6 & 2.7; Days 17-24 Cytokine Mix 
 
 
C 
 
 
 
 
 
 
 
 
 
 
 
 
2.4.2.11 Days 24-31 
 
Although the complete protocol is 31 days it was not necessary to continue 
differentiation beyond day 24 for the purposes of this research.  
 
 
 
 
 
Component [Final] [Stock] 250ml 500ml 
Iscoves Basal Media Base Base 240mL 474mL 
BSA  1% 25% soln. 10mL 20mL 
Insulin 10µg/mL 10mg/mL 250µL 500µL 
Transferrin 200µg/mL 50mg/mL 1.0mL 2.0mL 
β-mercaptoethanol 0.1mM 50mM 500µL 1mL 
Lipid Mixture 1   1.25mL 2.5mL 
Ethanolamine   10µL 20µL 
Factor [Final] [Stock] 1mL 
(1x) 
1mL 
(6x) 
2mL 
(6x) 
Hydrocortisone 1µM 1mM 1µL 6.0µL 12.0µL 
SCF 20ng/mL 50ng/µL 0.4µL 2.4µL 4.8µL 
IGF I 20ng/mL 100ng/µL 0.2µL 1.2µL 2.4µL 
IL3 6.7ng/mL 50ng/µL 0.134µL 0.8µL 1.6µL 
IL11 6.7ng/mL 50ng/µL 0.134µL 0.8µL 1.6µL 
EPO 3U/mL 10U/µL 0.3µL 1.8µL 3.6µL 
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2.4.3 Haematopoietic differentiation of CD34+ cells 
2.4.3.1 Day 0 
 
Prior to cell thawing the appropriate volume of ISHIT medium was prepared (Table 2.8) 
with D0-D8 cytokines (Table 2.9) and pre-warmed to 37°C. A vial of CD34+ cord 
blood cells was removed from liquid nitrogen storage and warmed by hand until ice 
crystals had almost disappeared. The vial was then opened in the hood and the cell 
suspension transferred to a 50mL centrifuge tube. 9mL of pre-warmed ISHIT medium 
was added drop-wise until the cell suspension had been diluted 1:10. The cells were 
then centrifuged at 300g for 10 minutes and the supernatant aspirated to waste. The 
pellet was resuspended in 1mL of ISHIT medium and a sample taken for counting using 
the trypan blue exclusion method. Cells were then seeded at 1 x 104 cells /mL in 
prepared medium and incubated at 37oC, 5% CO2. 
 
Table 2.8; ISHIT (Iscoves, Serum, Heparin, Insulin, Transferrin) Medium 
 
Component [Final] [Stock] 500ml 
Iscoves Basal Media Base Base 472mL 
Serum (Human AB+) 5% 100% 25mL 
Heparin 3U/mL 5000U/mL 0.3mL 
Insulin  10µg/mL 10mg/mL 500µL 
Transferrin 200µg/mL 50mg/mL 2.0mL 
 
Table 2.9; Days 0-8 cytokines 
 
Component [Final] [Stock] 1ml 
1X 
10ml 
1x 
1ml 
10x 
SCF 60ng/mL 50ng/µL 1.2µL 12µL 12µL 
IL3 5ng/mL 50ng/µL 0.1µL 1µL 1µL 
EPO 3U/mL 10U/µL 0.3µL 3µL 3µL 
Hydrocortisone 1µM 1mM 1µL 10µL 10µL 
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2.4.3.2 Day 2 
 
Cells were counted using the trypan blue exclusion method. Cells were pooled into a 
50mL centrifuge tube and centrifuged at 300g for 5 minutes. The supernatant was 
removed and cells resuspended in 1-2mLof ISHIT medium with day 0-8 cytokines 
added (Table 2.8/2.9). An adequate volume of pre-warmed (37°C) ISHIT/Day 0-8 
medium was added to a cell culture flask so that the final cell density would become 2 x 
104 cells /mL upon addition of the cell suspension. Cells were incubated at 37°C, 5% 
CO2. 
 
2.4.3.3 Day 4 
 
Cell density was adjusted to 4 x 104 cells /mL (using Day 2 protocol) 
 
2.4.3.4 Day 6 
 
Cell density was adjusted to 6 x 104 cells /mL (using Day 2 protocol) 
NB. Cells were frozen at Day 6 for recovery and expansion at a later date (See freezing 
protocol below). Almost all experimental work was carried out using cell banks which 
were resuscitated at day 6.  
 
2.4.3.5 Day 8 
Cell density was adjusted to 1-3 x 105 cells /mL same with Day 8-11 cytokines (Table 
2.10) 
 
 
 
 
 
 
 
 
 
69 
 
Table 2.10; Days 8-11 Cytokines 
 
 
 
 
 
 
 
 
2.4.3.6 Day 11 
 
Cell density was adjusted to 5-10 x 105 cells /mL in ISHIT medium with Day 11-25 
cytokines (Table 2.11) 
 
Table 2.11; Days 11-25 Cytokines 
 
 
 
 
 
 
 
2.4.3.7 Day 15 
 
Cell density was adjusted to 1-10x 106 cells /mL in ISHIT medium with fresh Day 11-
25 medium (Table 2.11). 
 
2.4.3.8 Days 18-22 
 
Cell density was adjusted to 1-10x 106 cells /mL in ISHIT medium with fresh Day 11-
25 medium (Table 2.11). 
 
Component [Final] [Stock] 1ml 1X 10ml 
1x 
1ml 
10x 
SCF 10ng/ml 50ng/  0.2µl 2µl 2µl 
EPO 3U/ml 10U/  0.3µl 3µl 3µl 
Hydrocortisone 1 M 1mM 1µl 10µl 10µl 
Transferrin 300µg/ml 50mg/ml 6µl 60µl 60µl 
      
Component [Final] [Stock] 1ml 
1X 
10ml 
1x 
1ml 
10x 
EPO 3U/ml 10U/  0.3µl 3µl 3µl 
Transferrin 300µg/ml 50mg/ml 6µl 60µl 60µl 
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2.5 Haematopoietic Growth Factors 
 
Table 2.12; List of growth factor manufacturers and reconstitution medium 
 
Factors Supplier Mixing Agent 
BMP4 R and D Systems 
4mM HCl with 0.1% 
BSA 
VEGF165 Peprotech PBS/0.1% BSA 
Wnt3A R and D Systems PBS/0.1% BSA 
Activin A Peprotech PBS/0.1% BSA 
Inhibitor VIII Calbiochem DMSO 
FGFa Peprotech PBS/0.1% BSA 
SCF 
Invitrogen/clinical 
Biovitrum AB PBS/0.1% BSA 
b-estradiol Sigma Ethanol/Medium 
IGF2 PeproTech PBS/0.1% BSA 
TPO PeproTech PBS/0.1% BSA 
Heparin Sigma Water 
IBMX Sigma DMSO 
Hydrocortisone Sigma Ethanol/Medium 
Flt3L PeproTech PBS/0.1% BSA 
IL-3 PeproTech PBS/0.1% BSA 
IL-11 PeproTech PBS/0.1% BSA 
EPO Roche PBS 
IGF1 PeproTech PBS/0.1% BSA 
 
The 18 growth factors listed were supplied and prepared as shown in the table. 
Although every effort was taken to keep conditions the same between laboratories it is 
suspected that medium preparation and variation in manufacturer lots could have had an 
impact on the differentiation process. 
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2.6 HL60 and J774 Cell Maintenance 
 
J774/HL60 cells were cultured in cell culture flasks in RPMI 1640 cell culture medium 
supplemented with 10% Fetal Bovine Serum (FBS). Prior to subculture the appropriate 
volume of media was decanted into a 50mL centrifuge tube and pre-warmed to 37°C. In 
the case of J774 cells whereby the cells were adherent a cell scraper was used to 
separate cells from the cell culture flask surface. A sample of the cell suspension was 
then taken using a pipette and counted on a haemocytometer using the trypan blue 
exclusion method. The appropriate volume of cell suspension was then centrifuged in a 
centrifuge tube at 100g for 5 minutes and resuspended in cell culture medium at a 
volume of 3-5 x105 cells/mL. Cells were left in incubator at 37°C 5% CO2 and 
subcultured every 3-4 days depending on confluency. 
 
2.7 Cell Culture Analysis 
 
2.7.1 Cytospin 
 
Cells were centrifuged at 300g for 5 minutes and resuspended in Dulbecco’s PBS 
(Ca2+/Mg2+ free) to a concentration of 1 x106 cells/mL. The required number of cytospin 
slides were prepared (with slide, filter and funnel as specified) and 100µL aliquots 
transferred to the sample well of the funnel. Once loaded the rotor was balanced and the 
cytocentrifuge (Tharmac GMBH) run at 450 rpm for 4 minutes. The cytospin slides 
were removed and allowed to air dry for 1 minute. The slides were then stained using 
Rapid Romanowsky stain pack (TAAB) by first dipping into solution A ten times to fix. 
This was followed by immersion in Solution B for 1 minute 30 seconds and solution C 
for 15 seconds. The slides were rinsed in deionised water and allowed to air dry before 
mounting in DePeX Mounting medium (Sigma). The slides were then be analysed under 
a microscope. 
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2.7.2 Microscopy 
 
Several microscopes were used during the project as follows; 
A) Tissue Culture Microscope – A Nikon Eclipse with DS-Qi1Mc 12 bit camera 
was used to capture images of all cells grown in the tissue culture laboratory. 
B) Colour Microscope – A Zeiss Axioscope fluorescence microscope with Canon 
EOS 60D digital camera was used to capture colour images of cytospin slides. 
C) Experimental microscope A – A Zeiss AxioObserverD1 fluorescence 
microscope was used initially to capture images of the cell culture device and 
biosensors. 
D) Experimental microscope B – Part-way through the project a Leica DMi8 was 
purchased and used with a Leica DFC camera for cell culture device images. 
Leica LAS X software and ImageJ were used for image analysis 
 
 
2.7.3 Flow Cytometric Analysis Preparation 
 
A FACSCalibur™ flow cytometer (BD Biosciences) was calibrated using four colour 
BD CaliBRITE™ beads and BD FACSCompTM software. BD CellQuestTM Pro 
Software was opened and prepared for data collection (See BD FACSCalibur™ 
Instructions for Use). A cell count and viability analysis were performed using the 
trypan blue exclusion method. Then a sufficient number of cells (1 x105 per test) were 
centrifuged at 300g for 5 minutes and resuspended in a suitable volume (100µL per test) 
of FACSFlow™ sheath fluid (BD Biosciences). The cell samples were kept chilled/on 
ice throughout remaining steps. 
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2.7.4 Antibody Staining 
 
In order to analyse antigenic markers micro centrifuge tubes were first labelled 
according to antibody/isotype stains and 100µL cell suspension decanted into each. 
Antibodies or isotypes were added so that antibody and isotype protein concentrations 
were equal (as obtained from BD Biosciences). The cells were then incubated in the 
dark at 4°C for 20 minutes. During this time flow cytometry tubes (BD Falcon™) were 
labelled according to antibodies/isotypes and filled with 200µL each of FACSFlow™ 
sheath fluid. Stained cells were removed from incubation and centrifuged at 300g for 5 
minutes. The supernatant was discarded and the stained cells resuspended in 100µL 
FACSFlow™ before decanting into the labelled flow cytometry tubes. Each tube in turn 
was placed on the FACSCalibur™ sample injection port and run on high until 10,000 
events had been collected for each sample. In depth analysis was completed using 
FlowJo software. 
 
2.7.5 Apoptosis/Necrosis  
 
Apoptotic Phosphatidylserine (PS), a hallmark of apoptosis, was stained using 
Apopoxin Green Indicator (Ex/Em = 490/525 nm) and for necrosis a membrane 
impermeable dye, 7-aminoactinomycin D (7-AAD, Ex/Em = 546/647 nm) was used 
(Abcam). For each test 1 x105 cells were centrifuged at 500g for 5 minutes and 
resuspended in 200µL assay buffer. 2µL of Apopoxin green and 1µL 7-AAD were 
added and the cell suspension vortexed before leaving in the dark at room temperature 
for 30 minutes. Prior to flow cytometric analysis 300µL of assay buffer was added to 
increase volume. Apopoxin green fluorescence was quantified on the FL1 channel and 
necrosis/7-AAD on FL3. Unstained cell samples were used as controls. 
 
2.7.6 ROS 
 
An ROS staining kit was purchased from Abcam. The deep red dye (Ex/Em = 650/675) 
reacts with ROS to generate deep red fluorescence which is detectable by flow 
cytometry. The ROS deep red dye was reconstituted by adding 40µL DMSO to the vial 
and mixing by pipetting. Cells (1 x105/test) were centrifuged at 300g for 5 minutes and 
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resuspended in 200µL assay buffer. 0.4µL of ROS stain was added (per 200µL sample) 
and the cell suspension vortexed before placing in a 37°C incubator for 30 minutes. The 
fluorescence intensity was then measured in the FL2 channel. Unstained cells were used 
as controls. 
 
2.7.7 Mitochondria 
 
A mitochondrial staining kit was purchased from Abcam. The kit uses a proprietary dye 
that selectively accumulates in mitochondria via the mitochondrial membrane potential 
gradient. A working stock was created by adding 20µL of the MitoGreen indicator to 
10mL of assay buffer. The cells (2 x105/test) were centrifuged at 1000rpm for 5 minutes 
and supernatant removed to waste. The cells were resuspended in 100µL of prewarmed 
cell culture media with an equal volume of the working MitoGreen solution. The cells 
were vortexed and incubated at 37°C for 60 minutes. The cells were then washed twice 
in DPBS before flow cytometric analysis in the FL1 channel and/or microscopic 
analysis. 
For microscopy cells were centrifuged onto slides using a cytocentrifuge (450 rpm for 4 
minutes) and images captured immediately in a dark room at 100ms. 
 
2.7.8 Hif-1-α 
 
Alexafluor 647 mouse anti-human Hif-1-α was purchased from BD Biosciences. Prior 
to the antibody staining described cells were first permeabilized in 4% 
paraformaldehyde. 
 
2.8 Flow Cytometry Analysis  
 
2.8.1 CD Markers 
 
In order to keep identical analysis methods between laboratories for data comparison the 
same methods were adopted at Heriot Watt University as those used at Glasgow 
University. As shown in Figure 2.1 the isotype population was first gated to separate 
live cells from dead cells and debris. The grid was then adjusted so that the population 
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was situated in the negative fluorescence (Lower Left) quadrant. These settings were 
then applied directly to the positively stained sample. The cells were considered 
positive/negative for the CD marker in question according to which quadrant the cells 
were situated. In the example shown the cells are 99.924% (0.024%+99.9%)  positive 
for CD71, 99.965% (0.065%+99.9%) positive for CD235a and 99.9% positive for both 
CD71 and CD235a. 
 
 
 
Figure 2.1 Flow Cytometric Analysis of CD Markers; (A) The isotype control cells 
were gated and then (B) the quadrant adjusted to contain the population in the 
negative. These parameters were then transferred to the positively stained 
population (C) and (D).  
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2.8.2 Apoptosis and Necrosis 
 
The unlabelled (control) and apoptosis/necrosis stained cells were gated in the same 
way as the CD markers (Figure 2.2). Each gated sample was then assessed for mean 
fluorescence intensity (MFI) using the median as calculated by FlowJo (since flow 
cytometry samples do not exhibit normal distribution it is standard procedure to use the 
median). The positive samples were then normalised using the negative control 
(unlabelled) populations [78]. 
 
 
Figure 2.2 Flow cytometric analysis of Apoptosis. (Left) Cells were gated as before 
and the mean fluorescence intensity (MFI) was calculated using FlowJo Software. 
(Right) Histogram showing Unlabelled (Red) and Apoptotic (Blue) samples. The 
Positive MFI was normalised using the negative/unlabelled sample. Necrotic MFI 
values were calculated in the same way. 
 
2.8.3 Enucleation 
Since cytospin counts are not representative of whole populations of cells flow 
cytometry was also used as a secondary method to track enucleation. Since Forward and 
Side Scatter only account for size and complexity of particles (cells or otherwise) a 
nuclei stain DRAQ5™ (Abcam) stain was used to ensure the correct population was 
identified as nuclei (Figure 2.3).  
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Figure 2.3 Flow cytometric analysis of enucleation. (Left) Nuclei were gated as 
before. (Right) Nuclei shown as positive for DRAQ5™ (PerCP) staining. 
 
2.9 Statistics 
 
Where appropriate students T-tests were performed using SPSS statistical Analysis 
software and results were considered significant at the level of P ≤ 0.05 (*), P ≤ 0.01 
(**) or P ≤ 0.00 (***). Unless otherwise stated all experiments were completed in 
triplicate.  
Pearson’s product moment correlation was also used where appropriate to gauge 
strength of correlations. Statistical significance was estimated as above and correlation 
strength according to the following; 
 
 
Coefficient, r 
Strength of Association Positive Negative 
Small .1 to .3 -0.1 to -0.3 
Medium .3 to .5 -0.3 to -0.5 
Large .5 to 1.0 -0.5 to -1.0 
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2.10 Computational Fluid Dynamics (CFD) 
 
The flow environments of the cell culture device, capillary device, 500mL Integra 
Cellspin spinner flask and Celligen BLU Bioreactor were characterized by solving 
Navier-Stokes equations with specified boundary conditions using Comsol Multiphysics 
4.4 package (Comsol, Hatfield, UK). The geometries were drawn directly into Comsol 
or in some cases in 2D in AutoCAD before importing. Two-dimensional axisymmetric 
models were selected for the capillary device since there are two planes of symmetry. 
Axisymmetric models were chosen over 3D since at the low Reynolds numbers 
calculated for these capillaries there should be no instabilities in laminar flow, pressure 
or velocity and the resultant simulations are mathematically in balance cylindrically. 
The advantages of modelling asymmetrically are three-fold. Firstly it allows for an 
increase in meshing density so that the viscous boundary layer has been resolved 
sufficiently to evaluate for shear forces in the flow. Secondly it would be difficult to 
produce an accurate 3D mesh over the centreline of the tube which supports the valid 
assumption of axisymmetric flow and finally it reduces solving time and memory 
[verbal communication, Alan McGuinn].  
The minimum element size used was 0.0159 µm. The kinematic viscosity of cell culture 
media at 37°C was could not be determined experimentally and was assumed to be 7.8 
x10-4 Pa .s as obtained from literature [79]. The density of the media was obtained 
experimentally to be 991.348 kg/m3 by weighing 500mL of cell culture media and 
subtracting the weight of the vessel. 
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Chapter 3 - Characterisation of Haematopoiesis 
 
3.1 RC9b and SFC i55 iPS cells 
 
The first step in the transformation of the haematopoietic differentiation protocol into an 
industrial bioprocess was to ensure the procedure was transferrable and could be run 
successfully across all laboratories in the consortium. The protocol was developed and 
performed efficaciously at Mountford Laboratories, University of Glasgow, hence 
initially all data produced at Heriot Watt University was analysed for equivalency. 
Aside from ensuring that cells were morphologically and physiologically identical it 
was paramount that the same proliferation (expansion) rates were attainable to ensure 
the robustness of the protocol prior to experimentation and eventually high volume 
bioreactor culture.   
 
3.1.1 Morphology 
 
Differentiation cultures were observed daily under a microscope to assess morphologic 
similarities/differences between laboratories. Pictures at Mountford Laboratories were 
taken using a Leica DMIL LED microscope and Nikon Digital Sight DS-L1 colour 
camera at x50 magnification (Figure 3.1) whilst those at Heriot Watt were taken using a 
Nikon Eclipse microscope with a DS-Qi1Mc monochrome camera at x100 
magnification (Figure 3.2). Despite the contrast in imagery it is clear the cells are 
morphologically akin to one another.  
At days 2-3 of the protocol stem cell ‘squares’ (cut from stem cell monolayers at day 0)  
had become more rounded/tubular and abundant (Figure 3.1 and 3.2 A/B) forming 
embryoid bodies (EBs). At Day 3 the EBs were mechanically separated and by day 5 
some of the cells had begun to attach to the substrate surface (Figure 3.1 and 3.2 C) and 
branch out to form colonies (Figure 3.1 and 3.2 D). At day 8 proerythroblasts had begun 
to bud off from the colonies (Figure 3.1 and 3.2 E) and proliferate rapidly. By day 9/10 
almost all cells were in suspension (Figure 3.1 and 3.2 F).  
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Figure 3.1; Cells at progressive stages in the haematopoietic differentiation 
protocol taken at Mountford Laboratories. (A) Day 2; Embryoid bodies are 
formed from ‘squares’ cut from stem cell monolayers at Day 0. (B) Day 3; EB 
aggregates become larger and more rounded/tubular. At Day 3 EBs are 
mechanically separated and reseeded. (C) Day 5; Separated cells begin to attach to 
substrate surface. (D) Day 7; Adherent cells branch out to form colonies/networks. 
(E) Day 8; Proerythroblasts bud off of colonies. (F) Day 9; Proerythroblasts begin 
to proliferate rapidly. 
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Figure 3.2; Cells at progressive stages in the haematopoietic differentiation 
protocol taken at Heriot Watt Laboratories. (A) Day 2; Embryoid bodies are 
formed from ‘squares’ cut from stem cell monolayers at Day 0. (B) Day 3; EB 
aggregates become larger and more rounded/tubular. At Day 3 EBs are 
mechanically separated and reseeded. (C) Day 5; Separated cells begin to attach to 
substrate surface. (D) Day 7; Adherent cells branch out to form colonies/networks. 
(E) Day 8; Proerythroblasts bud off of colonies. (F) Day 9; Proerythroblasts should 
begin to proliferate rapidly but appear unchanged from Day 8. 
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The main/only difference to be noted between the images for each laboratory is that at 
Heriot Watt Laboratories there was no observable proliferation, (Figure 3.2E/3.2F) the 
images for day 8 and 9 appear very similar. The interchangeable images for Mountford 
Laboratories (Figure 3.1E/3.1F) exhibit distinct proliferation.  
 
3.1.2 Marker profile 
 
A defined panel of pluripotent and haematopoietic antigenic markers were detected by 
flow cytometry at days 0 and 10 of the protocol to gauge whether cells were  the correct 
phenotype prior to and in the midst of differentiation (in most instances cells did not 
expand enough to assess markers at later stages in the protocol). Day 0 pluripotency 
markers obtained at Heriot Watt Laboratories were erratic and frequently lower than 
those achieved at Mountford Laboratories (Figure 3.3).  
 
Figure 3.3;  Comparison of average Day 0 pluripotency markers obtained for 
RC9b/SFC i55 cell lines at Heriot Watt University alongside a representative 
culture from Mountford Laboratories. Pluripotency markers tested at Mountford 
Laboratories were consistently higher and more reliable than those collected at 
Heriot Watt Laboratories which may have impacted on the differentiation process 
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It has been suggested that a deficiency in pluripotency markers denotes an inability to 
differentiate down a desired lineage. This may have impacted on cell phenotype later 
stages of the protocol and possibly proliferation/expansion. At Day 10 whilst most of 
the markers (CD235a/CD71/CD43/CD31) appeared stable and on target, immature cell 
markers CD45 and CD34 were significantly higher than those recorded at Mountford 
Laboratories (Figure 3.4).  
 
 
Figure 3.4; Comparison of average Day 10 antigenic markers obtained for RC9b 
differentiations at Heriot Watt University compared with a representative culture 
from Mountford Laboratories. Although CD43/CD31/CD235a/CD71 were 
constant, immature cell markers CD34 and CD45 remained high 
 
Although microscopic observation suggested that cells were morphologically identical, 
the analysis of cell phenotype suggested a state of arrested development. This may have 
been the cause of insufficient proliferation/expansion levels achieved at Heriot Watt 
University. 
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3.1.3 Expansion 
 
Training on the haematopoietic protocol was initially completed at Mountford 
Laboratories between November 2012 and June 2013 before attempting to transfer the 
process to Heriot Watt University.  During this time, trials of the protocol were 
completed within the target expansion range routinely achieved by Mountford 
Laboratories (Figure 3.5).  
 
 
Figure 3.5; Typical expansion range (grey) at Mountford Laboratories compared 
with trials at Mountford (black) Heriot Watt Laboratories (red) and expansion 
achieved with Faulty/Recalled Media (green).  
 
 Following the transfer of the protocol to Heriot Watt University in July 2014, the same 
levels of expansion could not be achieved. Due to the inconsistencies in pluripotency 
markers replacement cells were recovered from Mountford Labs in January 2015 and 
new cell banks generated with improved pluripotency markers (SSEA4 >95%, TRA-
160 >95%, SSEA3 >50%). Unexpectedly, expansion levels achieved using the fresh cell 
lines were inferior, particularly in the crucial embryoid body stage of development 
which had not been experienced prior. Large crystals were found residing in the media 
(Figure 3.6) and it was believed that these could have affected osmotic concentration. 
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Stem cells are extremely sensitive to environmental changes (be they biological or 
physical) and it was suspected that these crystals were the cause of further depreciated 
cell numbers. Consequently the specialized cell culture media (Stemline® II, 
ThermoScientific) was deemed unfit for use for the period January to June 2015 and 
recalled with no imminent replacement. One of the drawbacks of the project was that 
this specialized media was indispensable to the haematopoietic differentiation protocol 
and since its composition was unknown no replacement could be found. 
 
 
 
Figure 3.6; Large red crystals found in Stemline® II cell culture media 
 
From July 2015 onwards, due to volatile reagents, the instability of the cell lines and the 
irreproducibility of the phenotyping/expansion data, work with RC9b and SFC i55 cell 
lines was halted in favour of CD34+ cord blood stem cells. It must be noted however 
that some of the preliminary data contained in this research was obtained using the 
RC9b cell line.  
This preliminary work with pluripotent stem cells is deemed scientifically valuable 
since it emphasizes some common issues faced in making stem cell therapies clinically 
and commercially viable as shall be discussed in depth in Chapter 7. 
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3.2 CD34+ Cord Blood Cells 
 
Similar to the RC9b and SFC i55 work, all data produced for CD34+ cells at Heriot 
Watt Laboratories was compared to that of Mountford Laboratories for equivalency. 
Since there were no significant differences between laboratory data in any category, 
only results for Heriot Watt Laboratories are listed. The following sections describe 
normal haematopoietic development of CD34+ cells prior to experimentation. Since 
CD34+ cells are banked at day 6 and must be resuscitated and cultured for 24h prior to 
use, all data begins at day 8 and ends at day 21, when cultures were terminated due to 
lack of further growth/expansion. 
 
3.2.1 Morphology 
 
CD34+ cord blood stem cells grow entirely in suspension since they are already germ 
layer specified Haemangioblasts. There is little distinction to be made at progressive 
stages of differentiation by microscopy (Figure 3.7) and so in order to improve and 
standardise imaging across laboratories, a cytocentrifuge was purchased and used in 
conjunction with Rapid Romanowsky staining. Below (Figure 3.8) are stained cytospin 
pictures taken using a Zeiss Axioscope and a Canon EOS 60D digital colour camera at 
x40 magnification.  
 
 
 
Figure 3.7; (A) Day 11 and (B) Day 18 of CD34+ Cord Blood Differentiation 
protocol taken with Nikon Eclipse microscope at x10 magnification.  There were 
no discernible morphological differences between the images apart from cell size, 
which decreases over progressive days of the protocol 
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Figure 3.8; Cytospin pictures (x40 magnification) with genetic material (blue) and 
haemoglobin (red) staining. (A) Day 8-11; Cells are large and exhibit dark 
nuclear/mitochondrial staining. Blebbing can be seen at the edges of largest cells 
representing upregulated exocytosis. (B) Day 11-14; A mixed population of larger 
cells and smaller enucleated cells. Cells still appear blueish in colour representing 
retainment of mitochondrial genetic material. (C) Day 14-17; Cells become more 
uniform in appearance, enucleate further and begin to lose their blue hue. (D) Day 
18-21; almost all cells have enucleated and have distinct colour and appearance of 
reticulocytes (immature erythrocytes). NB. Scale bars are not included for these 
images since the cytospin procedure stretches and distorts cells. 
 
The cytospin images capture four observable stages of haematopoietic development. As 
well as morphological analysis, cytospin images were also used in combination with 
flow cytometry data to measure enucleation on each day of the protocol. 
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3.2.2 Enucleation 
 
Flow cytometry images show that enucleation begins as early as day 11 (Figure 3.9) 
when for the first time, two distinct populations appear on the forward/side scatter plots 
(which signify ‘event’ size/complexity). 
 
 
 
Figure 3.9; Forward and Side Scatter (FSC/SSC) images obtained by flow 
cytometry. (A) Day 10 of protocol, cells appear as a single population. (B) Day 11 
of protocol, ordinarily two populations are visible as 0-4% of cells have enucleated. 
(C) Day D12 of protocol, 6-12% enucleation and D16, 20-30% enucleation 
 
 Over the following days the nuclei population increases gradually and plateaus at day 
16 at approximately 25% of the population (Figure 3.10A). Cytospin pictures confirm 
that enucleation is at its’ height between days 15 and 18, peaking at day 16 (Figure 
3.10B). 
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Figure 3.10; (A) Nuclei population counts for each day of the protocol obtained 
using FSC/SSC flow cytometry plots. (B) Enucleation counts for each day of the 
protocol using cytospin images. Both methods confirm that enucleation is at its’ 
height between days 15 and 18, peaking at day 16. By day 21 75% of cells have 
enucleated. 
 
Despite the sustained increase in enucleation post day 16 the mean nuclei population 
remained <25%. This was due to the population being marked for apoptosis by 
exposure of phospatidylserine (PS) on the nuclear membrane (Figure 3.11) showing that 
nuclei are marked for apoptosis in the same way as cells and are continuously degraded 
throughout the protocol 
 
 
 
Figure 3.11; Apoptosis measured by Mean Fluorescence Intensity (MFI) of 
cells/nuclei marked with green (Ex490/Em525) PS sensor/MFI of unlabelled 
nuclei/cells. Nuclei exhibit elevated apoptosis levels in comparison to cell 
population, peaking at days 16, 19 and 21 
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3.2.3 Apoptosis and Necrosis 
 
The general cell population was evaluated for apoptosis and necrosis to assess cell 
health for the duration of the protocol, particularly post day 16 when cell number begins 
to decline. 
 
 
 
Figure 3.12; (A) Cellular apoptosis was labelled by apopoxin green (Ex490/Em525) 
PS sensor and detected by flow cytometry. A normal apoptotic rate of 2-6% is 
observed until day 16 when apoptotic cells more than double.  (B) Necrotic Cells 
were labelled by membrane impermeable red dye 7-aminoactinomycin D (Ex/Em 
546/647 nm).  Necrosis is high post thaw but remains low throughout the protocol. 
Typically cells necrose at a rate of <1%, necrosis increases slightly post day 16. 
 
 
Normally 2-6% of a cell population are apoptotic at any given time, as is the case for the 
entirety of the protocol, other than two peaks at days 16 and 21. Necrosis is usually ≤1% 
however it is characteristically high at day 8 post-thaw and there is also a peak at day 17 
which marks the degradation of apoptotic cells from the day previous. 
The apoptotic/necrotic peak at day 16/17 coincides with the enucleation peak and these 
events could conceivably be connected. It is possible that cells that do not enucleate are 
marked for apoptosis or that enucleation itself can be damaging to cells if not executed 
correctly. 
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3.2.4 Mitochondria 
 
Human embryonic stem cells contain mitochondria but their immaturity and paucity 
mean that they chiefly rely on glycolysis for energy. Fully developed red blood cells are 
devoid of mitochondria and similarly switch to glycolysis as their metabolic pathway. 
Theoretically both the RC9b and CD34+ cord blood cells should have 
less/underdeveloped mitochondria and therefore require less oxygen.  
 
 
Figure 3.13; Mean Fluorescence Intensity (MFI) of different types of cells stained 
with apopoxin green indicator (Ex/Em 490/520 nm) captured using flow cytometry. 
Cell lines J774 and HL60 exhibit the highest MFIs and RC9b and D8 cord blood 
cells have the lowest as predicted.  
 
Figure 3.13 shows that as predicted, the RC9b and CD34+ cells have lower mean 
fluorescence intensity of mitochondrial staining and therefore should require less 
oxygen than model cell lines J774 and HL60. Interestingly the SFC i55 cell line have 
more mitochondria than either of the other types of stem cell. This implies that although 
iPS cells are supposedly phenotypically the same as hESCs, metabolically they are not. 
The generation of iPS cells involves the manipulation of adult somatic cells to 
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transcribe embryonic genes and effectively become embryonic themselves but it is 
unclear what happens to their adult cellular machinery during this transition. Some very 
recent studies have shown that mitochondria experience DNA deletions during the 
modification and are hence mutated [64]. It is for such reasons that few (and none until 
2015) clinical trials involving iPS cells have been sanctioned and further investigation 
should be taken into their genetic and metabolic differences from embryonic stem cells 
in order to ensure their safety in cellular therapies. 
 
It was also important to note at which stage in the protocol mitochondria are extruded to 
evaluate whether oxygen concentration should be decreased over the duration of the 
protocol.   
 
 
 
Figure 3.14; MFI of cells stained with green mitochondrial label apopoxin (Ex/Em 
490/520 nm)/MFI of unlabelled cells as captured by flow cytometry. MFI decreases 
from day 8-12 before peaking at day 14 and then declines further. It is believed 
that this peak represents mitochondrial extrusion. 
 
Figure 3.14 shows that the mitochondrial MFI depreciates between day 8 and 12 before 
a peak at day 14. Following day 15 the mitochondrial signal diffuses further. Pictures 
taken of the cells at Day 8 and day 12 (Figure 3.15, below) show that mitochondria do 
indeed grow dimmer on progressive days of the protocol. However pictures taken at day 
14 show that mitochondria are almost extinguished and following this it is virtually 
93 
 
impossible to capture them by fluorescence microscopy. Therefore it is suggested that 
the peak MFI observed at day 14 is in fact a mass extrusion event and cells should 
require markedly less oxygen from this stage onwards in the protocol.  
 
 
 
Figure 3.15; Mitochondria captured using a Leica DMi8 fluorescence microscope 
and DMC camera using x10 (left) and x40 (right) magnification. Cells were 
labelled with apopoxin green (Ex490/Em520nm) at days 8 (A&B), 12 (C&D) and 
14 (E&F) of the protocol. Images show the fluorescence signal becoming weaker as 
the protocol progresses. 
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3.2.5 Marker profile 
 
CD34+ cells were analysed by flow cytometry at days 11, 15 and 18 of the protocol to 
coincide with media changes and conform to experimental design.  
 
 
Figure 3.16; Average haematopoietic cell markers for day 11, 15 and 18 captured 
by flow cytometry. CD71 and CD235a remain >90% throughout the protocol. 
Immature cell marker CD34+ is elevated at day 11 but drops off completely by day 
15/18. CD43/CD31/CD36 are in gradual decline. Platelet marker CD41a remains 
low. 
 
Figure 3.16 shows that at day 11 CD34+ remained high but had plummeted by day 
15/18 indicating maturation to haemangioblasts. CD43 and CD31 are transient 
haemangioblast markers which predictably drop off upon progression to the erythroid 
series whereby CD36 peaks signifying early erythroid cells. CD71 and CD235a 
remained high throughout the protocol since these are expressed by erythroid precursors 
and erythrocytes themselves.  CD41a remains low throughout cord blood differentiation 
since it is an early haemangioblast marker which has already diminished by day 11 but 
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it should be noted that this is also a platelet marker. CD45 is a leukocyte marker and 
marks some residual unsolicited differentiation to white blood cells. 
 
 3.2.6 Expansion 
 
CD34+ fold-expansion was not as great that obtained for RC9b/SFC i55 at Mountford 
Laboratories (cumulative fold-expansion x320000) however it was much more 
reproducible and the protocol was easily transferred to Heriot Watt University. Figure 
3.17 shows that the average expansion level achieved with CD34+ cells at Heriot Watt 
Laboratories was within the defined range achieved at Mountford Laboratories. 
 
 
 
Figure 3.17; typical expansion range at Mountford Laboratories (in grey) 
compared with Heriot Watt Laboratories (black). Red and green are minimum 
and maximum ranges respectively 
 
Cumulative fold-expansion for CD34+ cells was at a maximal value of x7940, around 
40 times less than for RC9b/SFC i55 cells yielding only 7.94x106 cells per 1x 104 
cells/mL seeded at day 0. However these figures suggest that the Celligen BLU 
bioreactor could still produce a unit of blood, especially since CD34+ cells are 
suspension cells more amenable to scale-up 
96 
 
 
 
 
Figure 3.18; Average expansion levels of CD34+ cord blood stem cells during 
haematopoietic differentiation protocol. Cells characteristically decline post-thaw 
but recover to form expansion peak day 9-11. Following day 16 the cells decrease 
in number since enucleated cells lose their capacity to proliferate. 
 
Figure 3.18 is a more in depth analysis of expansion at Heriot Watt using CD34+ cells. 
The cells are characteristically in lag phase post-thaw but then enter an expansion peak 
day 8-11 of the protocol with an overall average expansion of x14. This is also the most 
variable stage of the protocol as indicated by the error bars. Following this between 
days 12 and 15 is a second lesser expansion peak. From day 16 onwards the cells go 
into decline, the main reason being that they lose their capacity to replicate once they 
have enucleated. 
 
 
 
 
 
97 
 
3.3 Summary 
  
At the beginning of the project red blood cells were being generated from hESCs with a 
view to moving to iPS cells from carefully selected donors. This chapter has shown that 
unexpectedly, neither the RC9b nor SFC i55 cell lines were ideal candidates for a 
manufacturing process since the data collected was not reproducible between 
laboratories. It was also shown that SFC i55 cells were not metabolically similar to 
RC9b which yields further investigation. 
Cord blood stem cells seemed to pose a solution to this problem since their expansion 
and marker profile could be replicated although their fold-expansion was not as great. 
For the purposes of this research it was reasonable to move forward with CBS cells to 
find if they were ideal candidates for a GMP-compatible scalable process and yielded 
cells which were safe and compatible for blood transfusion.  
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Chapter 4 - Development of device 
 
4.1 Introduction 
 
Although the aim of the project was to scale-up production of red blood cells from 
human pluripotent stem cells, the reagent/materials cost to recurrently test a bioreactor 
or spinner culture vessel was so great that this was unfeasible. Instead an ultra-scale-
down (USD) approach was taken to reduce cost, gain precise control over the cell 
microenvironment and for its potential to be integrated into a sensing platform. A 
microfluidic cell culture device was proposed which was amenable to both adherent and 
suspension cells and could be used for online continuous monitoring of differentiating 
cells in response to a range of oxygen concentrations. It was also hoped that the device 
could be used to screen for other prolific metabolites such as carbon dioxide and 
glucose. 
Following the successful design and fabrication of the microfluidic device, it was 
acknowledged that the RC9b cell line did not expand enough (at Heriot Watt) to 
consume detectable volumes of the analyte (namely oxygen) and also that the cells were 
not plentiful enough for flow cytometric analysis. Hence a second, ‘mesofluidic’ device 
was also fabricated and is described in this chapter.  
 
 
4.2 Microfluidic cell culture device 
 
The preliminary design proposed for the microfluidic device was a simple straight 
channel with biosensor ‘microtrenches’ flanking a central cell culture chamber (Figure 
4.1). A number of more specific considerations of the design were made based upon 
methods described by Beebe et al. 2002 [80] and the successful differentiation of the 
RC9b cell line at Mountford Labs, Glasgow. 
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Figure 4.1; (A) Isometric view of the multilayer device as drawn into AutoCAD for 
laser cutting. Device top (red) with 1.58mm diameter inlet and outlet, compatible 
with common tubing sizes. Device Channel (yellow) which flowed over cell culture 
chamber and biosensor microtrenches (blue) and base (green). All pieces were 
laser cut into PMMA using an Epilog laser cutter and then stacked to form the 
device (B), which was then thermal bonded using ethanol. Inlet/Outlet holes were 
drilled and tubes attached using silicone sealant (C).  A third hole was drilled in 
the side of the device for addition of cells. (D) The side view (bottom, white) shows 
a 0.6mm chamber height with 0.2mm channel height. Once laminar flow is 
developed in the channel cells in the chamber area should be protected from 
displacement. 
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4.2.1 Cell culture chamber surface area 
 
Average cell counts of RC9b differentiated in 6-well plates designated that during the 
adherent stage cells grew to approximately 4.5 x105 cells/cm2 and for the suspension 
stage, 3.16 x106 cells/cm2. Since it was necessary to analyse cells by flow cytometry to 
allow comparison with data from other labs in the research consortium and this required 
a bare minimum 1.4 x106 cells, the proposed surface area for the cell culture device was 
0.44 cm2. 
 
4.2.2 Channel height 
 
RC9b differentiation was routinely carried out in 3mLs of media in 6-well plates with a 
surface area of 9.5cm2 giving a culture height h, of 3.1mm. For microscale culture h is 
typically 5-10 times smaller than macroscale, resulting in a channel/chamber height 
range of 310-620µm [80]. For ease of fabrication and to allow for cell expansion, a 
chamber height of 600µm was selected with 200µm height channels flanking either 
side.  
 
4.2.3 Effective culture time and critical perfusion rate 
 
Since the device had to be amenable to adherent and suspension cells, a central cell 
culture chamber (6.67 mm x 6.67 mm) with raised channels either side was proposed so 
that laminar flow would prevent the cells from being washed out of the device. With the 
channel width, length and height set as 6.67mm, 6.67mm and 0.6mm respectively the 
ECT was calculated as 14 hours by applying the channel height ratio (5.1) to the 
macroscale culture time (72 hours). Since the media should be replaced every 14 hours 
the Critical Perfusion Rate (CPR) was estimated as 3.8µL/hour, a velocity of 7.88 x10-7 
m/s [80]. 
 
4.2.4 Channel length 
One of the advantages of microfluidic devices is that diffusion is the governing force of 
mass transport, speeding up reaction times. The Péclet number (Pe) was calculated to 
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ensure that diffusion would dictate transport of oxygen in the device (rather than 
convection) using the following equation; 
 
 Where L is a characteristic length scale, U is the velocity magnitude, and D is the 
characteristic diffusion coefficient. In order for the effects of diffusion to exceed the 
effects of convection, the Péclet number must be <1. Since the diffusion coefficient of 
oxygen at 37°C is approximately 2.52 x10-5 cm2/s and the velocity calculated as 7.88 
x10-5 m/s; 
Pe = 1 =  L*7.88 x10-7 cm/s 
2.52 x 10-5 cm2/s 
 
 
Hence the maximum channel length which upholds diffusive action would be 32mm. It 
was therefore decided that a channels of 12mm ((12mm*2) +6.67mm= 30.67mm) would 
be placed either side of the cell culture chamber to allow room for microtrenches, while 
upholding diffusive transport [80]. 
 
 
4.2.5 Maintaining laminar flow 
 
The Reynolds number was calculated as <1 typical of microfluidic devices. This 
ensured that laminar flow would prevail inside the device. 
 
4.2.6 Material selection 
 
It was of paramount importance that the device be fabricated from a gas impermeable 
material (to conserve oxygen) which was biocompatible, hence poly-methyl 
methacrylate (PMMA) was chosen over polydimethylsilonane (PDMS). Materials were 
also selected based on affordability, biocompatibility, durability, chemical inertness and 
sterilization method. 
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4.2.7 Fabrication method 
 
Based on the device design and material specification, laser cutting into Poly-methyl 
methacrylate (PMMA, purchased from Easter Road Plastics) was chosen as the most 
suitable fabrication method. The device design was drawn as multilayer into AutoCAD 
2014 design software and then cut into layers of PMMA using an Epilog laser cutter as 
shown. The device layers were aligned and bonded on a hot plate with ethanol at 79°C 
for 30 minutes.  
 
4.2.8 Fittings and fixtures 
 
PEEK tubing, fittings and filters (IDEX health and Science) were purchased and used as 
supplied. A waste reservoir was fabricated from a Nalgene jar with a PEEK tubing inlet 
and a syringe filter vent, which were fastened using silicone sealant. A heat mat with a 
thermostat set to 37°C was placed underneath the culture chamber. A platform was 
constructed from aluminium angle bars and PMMA which held the device, biosensors, 
media/waste reservoirs and heat mat in place so that the device could be transferred 
easily from hood to microscope. 
 
4.2.9 Mass flow rate controllers and pump 
 
Three mass flow rate controllers were purchased from AliCAT Ltd and set up for CO2, 
O2 and N2 according to the user manual. The cell culture media was continuously 
sparged with a predetermined air mix and the media withdrawn from the reservoir using 
a MilliGAT microfluidic pump.  
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4.2.10 Experimental set-up 
 
 
 
 
Figure 4.2; Schematic of experimental apparatus for microfluidic device. AliCAT 
mass flow controllers continuously sparged the media reservoir with a 
predetermined gas mix. The media was perfused using a MilliGAT microfluidic 
pump at a rate of 3.8µL/hour through the microfluidic device with in-house 
biosensors. The waste reservoir was connected downstream of the device. The 
apparatus was placed under a Zeiss Axioscope for in-situ image capture during 
cell differentiation. 
 
4.2.11 Experimental method 
 
The microfluidic device was placed in a laminar flow hood and attached to the 
MilliGAT microfluidic pump and media reservoir (upstream) and waste reservoir 
downstream. Ethanol was then perfused for >40 minutes followed by sterile DPBS and 
then air. Once sterile, media which had been warmed to room temperature was placed in 
the media reservoir and cells inserted by syringe at the designated inlet. The apparatus 
was removed from the hood and placed under the Zeiss Axioscope. The media reservoir 
was attached to the mass flow controllers for continuous gas sparging. After an hour, at 
which time the media/gas had equilibrated, the microfluidic pump was started. 
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4.2.12 Complications with device 
 
As prior mentioned the device was based upon the maintenance/differentiation of RC9b 
cells cultured at Mountford Laboratories, Glasgow. When the process was transferred to 
Heriot Watt University the cells did not proliferate well and the protocol was deemed 
non-transferrable. The device however was developed successfully for use with J774 
and HL60 cells with the possibility for use with other cell types. 
 
A new device was developed which was compatible with RC9b/CD34+ cord blood cells 
and it was decided to base the device design on 6-well plates to ensure analyte 
concentration/cell expansion. The rationale for continuing with a ‘mesofluidic device’ 
 
(rather than well-plates) was the continued use of the biosensors and in-situ imaging, 
with the cost effectiveness of a reusable device/equipment. The PMMA microfluidic 
devices had reoccurring problems with contamination and so it was devised that the new 
device be fabricated entirely from autoclavable materials. As was discussed previously 
due to time constraints and the high volume of laboratory and manufacturing work 
required on the project alternative polymers were not suitably researched at the time. It 
was also felt that alternative fabrication methods may take too much development hence 
every effort was taken to persist with the existing methods of fabrication. The MilliGAT 
pump was also prone to contamination during long-term use and was replaced with an 
AL-2000 Syringe Pump (WPI, Europe). 
 
4.3 Mesofluidic cell culture device 
 
The proposed design of the mesofluidic cell culture device was again a simple straight 
channel flowing over a central cell culture chamber. The surface area (9.5cm2), height 
of media (3.1mm) and ECT were all kept concurrent with a 6-well plate. The CPR was 
calculated as 43µL/hour 
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Figure 4.3; (A) Schematic of cell culture device chamber and channel. The surface 
area of the cell culture chamber was 9.42 cm2 and media height 3.1mm, closely 
resembling that of a 6-well plate. Channel depth was 2mm to accommodate tubing. 
The design was cut into Stainless Steel using a milling machine, as was the clamp. 
The top and bottom of the device were cut from borosilicate glass and the gaskets 
cut from silicone sheet. Once all parts were assembled inside the clamp (B) the lid 
was fastened using M4 hex bolts and nuts which were tightened to 1 Nm using a 
torque wrench. (C) Is a CFD simulation of shear stress inside the device. It was 
ascertained cells would not be susceptible to shear stresses exceeding 3 x10-4/s 
which is far below physiological shear stress. 
 
4.3.1 Material selection 
 
The mesofluidic device was fabricated from borosilicate glass (Newcastle Glass Ltd), 
stainless steel (The Metal Store) and silicone sheets (Silex Ltd). The Clamp had an 
aluminium base, stainless steel lid (The Metal Store) and stainless steel 
bolts/screws/gaskets purchased from Screw Fix. All materials were biocompatible and 
sterilisable by autoclave. Fittings and fixtures were as before. 
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4.3.2 Fabrication method 
 
The device chamber and channel were cut into stainless steel using a Bridgeport Milling 
machine. A 2mm hole was drilled into the side of the chamber so that cells could be 
injected and sealed with a M2 stainless steel hex screw. The inlet/outlets were 10-32 
coned ports so that IDEX health and Science fittings with PEEK tubing could be 
screwed directly into the device. The aluminium clamp base was also milled and 3.6mm 
holes for M4 screws were cut using a drill. Initially the clamp lid was made from 
aluminium but it warped under autoclave/screw pressure and so a stainless steel 
replacement was laser cut. Top and bottom glass pieces were made to measure and used 
as supplied from Newcastle Glass Ltd. The bottom glass piece was permanently 
attached to the stainless steel chamber using silicone sealant. Silicone sheeting was cut 
to size using a scalpel for use as a gasket to seal the glass lid. All parts were rinsed in 
acetone followed by deionised water to clean before assembly and autoclave to sterilise.  
 
4.3.3 Experimental set-up 
 
 
Figure 4.4; Schematic of mesofluidic experimental set-up. Media was pre-sparged 
with gas of pre-determined concentration and then loaded into an SGE gas tight 
syringe under sterile conditions. The syringe was placed on the AL-2000 syringe 
pump and perfusion through the device set at 43µL/hour. The biosensor was 
placed downstream of the device and was connected to the waste reservoir. The 
apparatus was left under a Leica Dmi8 microscope for in-situ imaging 
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4.3.4 Experimental method 
 
The apparatus was assembled (Other than the gas tight syringe and biosensor) and 
autoclaved for 15 minutes at 121°C. The gas tight syringe was sterilised by UV and the 
biosensor by passing ethanol for 40 minutes followed by sterile DPBS. Once all parts 
were sterile they were assembled in a laminar flow hood. Media (at room temperature) 
was drawn into the syringe and connected to the inlet tubing. Cells were added to the 
device by syringe/needle via the M2 inlet which was then screwed shut. Following 
assembly the apparatus was moved to the Leica DMi8 microscope and the AL-2000 
pump set to 43ul/hour. 
 
4.4 Biosensors  
 
4.4.1 Oxygen 
 
Ruthenium-tris (4,7-disphenyl-1, 10-phenanthroline) dichloride Ru (dpp) was purchased 
from Sigma-Aldrich (now Merck) its fluorescence is strongly reduced by molecular 
oxygen due to dynamic quenching. The complex was dissolved in ethanol to final 
concentration of 1mg/ml. The ethanol dissolved ruthenium was then mixed with PDMS 
polymer base and curing agent in volume ratio of 1:10:1 then stirred until evenly 
distributed. In the beginning the mixture was applied to ‘microtrenches’ but was later 
spin-coated onto circular coverslips. Once formed the biosensors were degassed for 30 
mins and cured over 3 hours at 65°C. Although the biosensors were developed 
successfully Sigma-Aldrich discontinued Ruthenium-tris (4,7-disphenyl-1, 10-
phenanthroline) dichloride Ru (dpp) mid-way through the project and despite every 
effort a good quality, affordable replacement could not be found. For the latter part of 
the project biosensors were instead purchased from Ocean Optics. 
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4.4.2 Glucose 
 
ConA-TRITC and FITC-dextran were prepared in DPBS at a mass ratio of 100:1 and 
then added to 4% (w/v) low melting agarose solution at 48°C to a final concentration of 
500:5 mg/mL. The microtrenches were then filled and allowed to solidify for 1 hour. 
Eight alternating coats of poly-allyl-amine hydrochloride (PAH) and poly-sodium 4-
styrenesulfonate (PSS) were then applied alternately (four each) allowing 30 minutes 
for drying between each application. Although this biosensor was effective in detecting 
glucose the PAH/PSS film could not be sterilized and hence this biosensor needs further 
development and was not used for experiments. 
 
4.4.3 Carbon Dioxide 
 
8-Hydroxypyrene-1,3,6-Trisulfonic Acid, Trisodium salt (HPTS) is a highly water-
soluble pH indicator which can be immobilized in hydrogels. Although it does not 
detect carbon dioxide per se it can be used to monitor the pH of the media which is a 
product of the fusion of carbon dioxide with the media (although cell metabolism also 
affects pH). Although several attempts were made to encapsulate HPTS in PDMS its 
fluorescence properties were lost during fabrication. Since HPTS requires ratiometric 
detection its use would have necessitated the purchase of an additional filter cube. 
Hence it was decided not to progress further with this biosensor although recently 
successful HPTS biosensors have been produced using other matrix materials.  
 
4.4.2 Chambers 
 
Initially biosensors for the microfluidic device were situated either side of the culture 
area in microtrenches however they were later housed in separate chambers. Biosensor 
chambers were drawn as multilayers in AutoCAD and cut into PMMA using an Epilog 
laser cutter. The biosensor was applied to the chamber base and the layers bonded using 
dichloromethane. Tubing was applied to inlets/outlets using silicone sealant. 
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4.5 Summary 
 
Two devices were successfully developed for use on the project (micro and mesofluidic) 
The microdevice encompassed all of the benefits that USD has to offer with 
significantly reduced media costs, easy integration into a microscopy platform and 
shortened reaction times (ECT). However laser cutting proved more difficult than 
anticipated, since considerable trial and error was necessary to optimise the 
microstructures, particularly when cut into thin (200µm) PMMA. Several months were 
also spent on bonding these devices using thermal bonding, UV adhesive, sheet 
adhesive, biocompatible wax and silicone sealant. Many of these methods were not 
compatible with ethanol which was necessary to sterilise the PMMA. Unfortunately 
information on bonding in microfluidics is scarce and is usually acquired through 
personal recommendations. Upon successful bonding of the device with ethanol and 
heat the leak-proof device was prone to serial contaminations, which was the rationale 
for switching to autoclavable materials in the mesofluidic device. This second device 
was successful from the onset armed with knowledge and experience from the failures 
of the microfluidic device. However many of the microfluidic advantages were lost 
since reagent usage and ECT remained unchanged. It was however amenable to use 
with biosensors and in-situ microscopy. 
In hindsight the development of three biosensors (in light of other difficulties 
experienced during the project) was overly ambitious, particularly since they were not 
amenable to sterilization methods. Again although there is abundant information on the 
development of biosensors, few of these mention sterilization methods or indeed 
compatibility to cell culture devices. [64][65][67]. This could be considered for future 
work in the development of microfluidic devices and biosensors. 
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Chapter 5 - Oxygen Experiments 
 
5.1 Introduction 
 
Oxygen is usually the principal limiting factor in the scale-up of bioprocesses. Industrial 
scale bioreactor cultures require constant oxygenation by sparging with mechanical 
mixing to ensure all gasses and nutrients are mixed homogenously.  Since the majority 
of cell death and damage is incurred through bubble damage, a reduction in sparge rate 
which does not limit oxygen would certainly be advantageous. There is evidence to 
suggest that human embryonic stem cells require less oxygen due to the paucity and 
immaturity of their mitochondria and that in some instances hypoxia is in fact beneficial 
since it reduces oxidative stress. It is unknown whether this is true of the RC9b or 
CD34+ cell lines but as shown in Chapter 3 their mitochondria are indeed subsidiary to 
more conventional cell lines. It was therefore anticipated that a reduction in oxygen 
concentration might improve culture health and expansion and it was hoped that by 
finding the respiration rate of cells at successive stages of the protocol it would be 
possible to calculate the critical oxygen concentration for scale-up to bioreactor culture. 
 
5.2 Ruthenium biosensor calibration 
 
A calibration was performed for each biosensor prior to use by flushing 37°C cell 
culture media through the chamber at 0 and 5, 10 or 21% oxygen (dependent on 
experiment) and recording fluorescence intensity at 100ms.  
 
Figure 5.1; Ruthenium biosensor at increasing oxygen concentrations from 0 to 
100%. Since the Stern-Volmer Equation becomes less reliable at high quencher 
concentrations the biosensor was calibrated at 0 and the maximum value (5, 10 or 
21% oxygen) as determined for each experiment. 
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Since ruthenium fluorescence is dynamically quenched by oxygen its fluorescence 
intensity diminishes with increased oxygen concentration (Figure 5.1) 
The I/Io ratio (as described previously) was then plotted against oxygen concentration 
(µg/mL) to find the Stern-Volmer constant. This could then be used to calculate how 
much oxygen was consumed during each experiment. 
 
 
 
 
Figure 5.2; Oxygen concentration (mg/L) with fluorescence intensity in presence of 
quencher (I) over fluorescence intensity in absence of quencher (Io) to gain Stern-
Volmer constant, in this instance -0.0947. This was calculated prior to each 
experiment and used to find the corresponding oxygen concentration for its 
duration 
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5.3 Preliminary device experiments 
 
Prior to and following each experiment the biosensors were tested for accuracy using a 
series of media with known oxygen concentrations. Device apparatus were set up as 
specified in Chapter 4. Images of biosensors and cells were captured at the beginning 
(T0) and the end of each experiment (Tn) as a minimum but where possible were taken 
every 24 hours. Cells were counted at the end of each experiment and experimental 
pictures were used for cell counting using ImageJ. For the J774 and RC9b trials cell 
counting was the only form of analysis but once experiments began with CBS cells they 
were removed from the device post-experiment and analysed for cell markers, 
apoptosis/necrosis, Hif-1-α, mitochondria, ROS and enucleation using flow cytometry. 
 
5.3.1 J774 Trials 
 
Preliminary tests with the cell culture device and biosensor were conducted with model 
adherent cell line J774 at ambient (21%) oxygen to ensure that the device was in good 
working order prior to use with RC9b cells.  
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Figure 5.3; J774 Murine macrophage cells grown in mesofluidic cell culture device 
at 21% oxygen captured at (A) 24 and (B) 48 hours with comparative cultures 
grown in a 37°C 5% CO2 incubator (C&D).  Although cells differ in growth 
pattern (cells grow in patches on treated cell culture flask surface) the cultures 
demonstrated similar rates of expansion 
 
Images captured at 24 and 48 hours (Figure 5.3) confirmed that adherent haemocytic 
cells were compatible with the culture device and could be cultivated over the extended 
periods of time required for RC9b differentiation (>48 hours). Cells were counted every 
24 hours throughout the culture period and compared with control cultures which were 
grown simultaneously in 37°C 5% CO2 incubators. There were no significant 
differences to be found between the cell counts and furthermore the ruthenium 
biosensor was used to successfully obtain an estimation of oxygen consumption per cell 
(between 13 and 92 amol cell-1 sec-1) which was within range of the literature value 
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recorded for J774 cells (31 amol cell-1 sec-1). Also of note is that the cells use markedly 
more oxygen during log phase than the stationary phase of growth 
The only perceptible difference between the culture images was the growth pattern, as 
J774 cells grew in patches on treated cell culture flask substrates rather than randomly. 
This was not considered a concern for RC9b cells since cells had been successfully 
grown on a number of substrates including glass. 
 
Table 5.1; Cell counts/doubling times for J774 cells grown in the device and 
incubator were markedly similar. The ruthenium biosensor was also used to 
successfully calculate oxygen consumption at 24 and 48 hours. Following the 
success of this experiment it was decided to trial the device with RC9b cells 
 
Hour 0 24 48 
I 50.43 55.76 57.19 
I/Io 0.378399 0.418382353 0.429089136 
O2 (ug/mL) 7.20 6.78 6.67 
Cell Count 
Device 1000000 1650000 3000000 
Doubling time - 33.22 27.83 
Cell Count 
Incubator 1000000 1600000 3060000 
 
 
 
5.3.2 RC9b trials 
 
Following the success of the J774 trials RC9b cells were cultured in the device from day 
3-7 of the protocol in hypoxic conditions (3% oxygen).  Images taken at Days 3, 4, 6 
and 7 show that growth in the device was far more expansive than in the incubator 
control cultures (Figure 5.4). At day 7 the cells were harvested and counted. Cell 
doubling time under hypoxic conditions was more than halved from 106.2 to 42.34 
hours. 
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Table 5.2; Cell counts/doubling time for RC9b cells grown in the device was more 
than halved in comparison to the control incubator culture. The ruthenium 
biosensor was also used to successfully calculate oxygen consumption at 72 hours 
following the experiment which indicated an oxygen consumption rate of 2.04 amol 
cell-1 sec-1 
 
Hour 0 72 
I 120.83 121.07 
I/Io 0.9112 0.913 
O2 (µg/mL) 1.71 1.65 
Cell Count Device 1000000 3250000 
Doubling time - 42.34 
Cell Count 
Incubator 
1000000 1600000 
Doubling time - 106.2 
 
 
 
Biosensor readings were taken at 0 and 72 hours. This experiment was only completed 
once due to aforementioned problems with the RC9b cell line and serial contaminations 
in the microfluidic PMMA device. The overall oxygen consumption rate of 
differentiating RC9b cells was calculated as 2.04 amol cell-1 sec-1 which is close to the 
experimental value for CBS cells (2-3.5 amol cell-1 sec-1, Figure 5.4). This result 
coupled with the amplified fold-expansion were considered very encouraging in terms 
of scale-up and await further investigation once the cell lines/reagents are more 
established.  
As described earlier the device was proposed for use with CD34+ cord blood cells and 
prior-tested with the model haemocytic suspension cell line HL60. 
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Figure 5.4; (A) Cells (At day 3 of protocol) in device 4 hours post-seeding (B) at 24 
hours and then 56 (C) and 72 (D) hours with comparable pictures of incubator 
cultures (E, F, G and H) 
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5.3.3 HL60 trials 
 
Since the device had already been established for long-term use with adherent J774 and 
RC9b cells, the main/only issue was to ensure it would work with suspension cells i.e. 
they would not wash out under flow conditions. Briefly, the device was trialled for 24 
hours with HL60 cells and it was found that cells remained in the device and 
proliferated normally.  
 
5.4 Cord blood device experiments 
 
5.4.1 Rate of oxygen utilization 
 
 
Figure 5.5; Oxygen Consumption Rates (amol cell-1 ml-1) of Differentiating CD34+ 
Cord Blood Cells at D11-14 and D15-18 at 5, 10 and 21% O2 in cell culture device. 
As predicted cells consumed more oxygen in the early stages of development as 
opposed to the latter stages. Oxygen consumption rate was significantly lower at 5 
and 10% oxygen when compared with 21% as indicated by asterisks. 
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As predicted CD34+ differentiating cells consumed less oxygen than the average for 
haemocytic cell types. Of the two time frames tested, D11-14 had the highest oxygen 
consumption, most likely due to their conserved mitochondria at this stage in the 
differentiation process. At 10% and especially 5% oxygen the cells consume markedly 
less oxygen and should have switched to anaerobic glycolysis as a main energy source. 
The D15-18 cells however seem less affected by hypoxic conditions since they should 
already have switched to glycolysis as their main energy pathway. 
 
5.4.2 Expansion 
 
 
 
Figure 5.6; Expansion for (A) D11-14 and (B) D15-18 at 5, 10 and 21% oxygen in 
cell culture device compared with incubator control cultures. Encouragingly D11-
14 cells grew marginally better in 5 and 10% oxygen in the device when compared 
with 21% oxygen. However none of the cultures grew as well as the incubator 
control cultures. D15-18 cells were less effected by oxygen level but similarly 
showed some improvement in expansion at 5 and 10% 
 
As anticipated CD34+ cells showed greater expansion at 5 and 10% oxygen tensions in 
comparison to 21% cultures carried out in the device. The marker profile was also 
experimentally interesting (next section) however the device cultures did not grow so 
well as the control incubator cultures, even at ambient oxygen. A large -80°C freezer 
which was placed next to the device apparatus was the expected cause of the lacklustre 
expansion since its substantial vibration caused the cells to shudder for prolonged 
periods. Following two rounds of experiments (from which Figures 5.5-5.8 are 
formulated) the apparatus was moved away from the -80°C freezer. Following this the 
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third round of experiments showed reduced expansion under hypoxic conditions in 
comparison to control cultures and hence the experiments were repeated in static 
conditions (Section 5.5) 
 
5.4.3 Marker profile 
 
 
Figure 5.7; Mean antigenic markers recorded following D11-14 experiments with 
5, 10 and 21% oxygen in device alongside control Incubator cultures. Most of the 
markers appear unaffected however CD34 and CD45 immature cell markers are 
significantly lower and higher respectively, for 5 and 10% oxygen. Additionally the 
CD41a platelet marker was significantly higher for 5 and 10% oxygen suggesting 
that hypoxia induces cells to produce platelets. However this effect was also 
observed in the device for 21% indicating that this effect could be a product of the 
device conditions, not necessarily oxygen concentration. 
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Figure 5.8; Mean antigenic markers recorded following D15-18 experiments with 
5, 10 and 21% oxygen in device alongside control Incubator cultures. As for D14 
most of the markers appear unaffected however CD34 markers are marginally 
lower and CD45 cell markers are higher for 5 and 10% oxygen. The CD41a 
platelet marker was significantly higher for 5 and 10 and 21% oxygen suggesting 
that either hypoxia, device conditions or both induce cells to produce platelets.  
 
Since the differences in the CD41a platelet marker were also observed in the ambient 
condition it was supposed they were attributed to either (a) differences in media 
imposed by perfusion system (b) mild long-term shear effects inflicted by the vibration 
of external equipment and/or perfusion system or (c) the combination of shear and 
hypoxia. It was also possible that the device conditions were having an effect on 
expansion and other antigenic markers. In order to investigate this further 5, 10 and 
21% oxygenated cultures were run as static cultures in cell culture flasks in a 37°C 
incubator.  
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5.5 Cord blood static cultures 
 
Since the device experiments yielded some unexpected results a secondary static culture 
experiment was devised to discover whether the platelet markers were a true product of 
hypoxia or whether they were induced by the mild shear environment of the device. 
These cultures were treated the same way as the control cultures only they were placed 
inside a closed chamber inside an incubator set at 37°C. The mass flow controllers 
(described previously) were set at the desired gas blend and the line led into the 
chamber with a vent at one side to allow for pressure.   
 
5.5.1 Expansion  
 
 
 
Figure 5.9; Experimental expansion/Control expansion i.e. levels >1 indicate that 
proliferation is not affected by low oxygenation. D11-14, typically the peak 
expansion period, exhibited remissive proliferation for both 5 and 10% oxygen. 
However for Day 15-18 following mitochondrial expulsion, expansion was similar 
to control cultures. By D18-21 expansion is improved in comparison to control 
cultures  
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In conflict with device cultures (and anticipated results) the CD34+ cells did not 
proliferate so well in hypoxic conditions as in the ambient. It was therefore deduced that 
expansion data for the device was unreliable and that the CD34+ cells do not proliferate 
well under hypoxic conditions before Day 14. These results were surprising since 
mitochondrial profiling had shown similar levels between RC9b and Day 8 CD34+ CBS 
cells and it was hoped that hypoxia would increase cell yield for both types of stem cell. 
However since these cells are isolated from different environments en vivo and are 
maintained differently in vitro perhaps too many assumptions have been made about the 
interchangeability of stem cells and their abilities to generate functionally identical 
cells. Encouragingly though in terms of scale-up, the cells did proliferate well in 
hypoxia from day 15 onwards, supporting the case that sparge rate can be substantially 
reduced at this stage. 
 
5.5.2 HIF-1- α 
 
All cells were analysed for Hypoxia-inducible-factor 1-alpha (HIF-1- α), however the 
results came back inconclusive. One explanation is that the oxygen tensions used during 
experimentation were not low enough although this seems unreasonable since it was 
shown that oxygen utilization was downregulated in response to both 5 and 10% 
oxygen, a hall-mark of the Hif-1 response. Another explanation is that CD34+ cells do 
not induce this response to hypoxia. This also seems unlikely since Hif-1 is highly 
conserved and moreover all nucleated cells in the human body are known to induce this 
response to hypoxia.  The most likely explanation is that flow cytometry is not a 
suitable analysis method for Hif-1-α as was initially thought. This would be better 
assessed by Western blot should the experiment be repeated. 
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5.5.3 ROS 
 
 
 
 
Figure 5.10; Reactive Oxygen Species Recorded by flow cytometry at Day 14, 18 
and 21 for CD34+ differentiating cells in low (5% and 10% combined) and 
ambient oxygen. Contrary to the hypothesis that cells in ambient oxygen have 
higher instances of reactive oxygen species, the profiles were very similar for each 
condition. Up to Day 14 Cells have a higher inclination for ROS 
 
It was conjectured at the beginning of this research that cells in hypoxic environments 
may benefit from lower occurrence of Reactive Oxygen Species (ROS).  However there 
were no apparent differences in ROS for any of the conditions tested. It was of note that 
before day 14 cells have higher incidence of ROS which may be due to retainment of 
mitochondria and/or nuclei. The similarities in ROS between the low and high samples 
may explain why there was little impact on expansion.  
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Initially it was anticipated that ROS would be naturally elevated in all ambient (control) 
cell cultures as a residue of cellular metabolism, able to diffuse in and out of cells in 
culture. However it would seem that ROS only accumulate inside cells as direct product 
of mitochondrial action. It is unclear what happens to mitochondria under hypoxia, 
some journals report downregulation of action and others biogenesis and upregulation. 
The experimental results are contradictory since it was shown that oxygen utilization 
was downregulated under hypoxic conditions however Figure 5.11 shows that the 
mitochondrial MFI was higher which would indicate upregulation/biosynthesis.  
Since it was earlier shown that mitochondria are extruded on day 14 of the protocol 
perhaps the increased MFI is a result of upregulated mitochondrial expulsion in 
response to hypoxia. It is hence difficult to speculate on the similarities of ROS between 
control and hypoxic conditions.  As before perhaps the analysis method was not 
sensitive enough since the difference in oxygen utilization (approximately 2 amol cell-1 
sec-1) between hypoxic and control cultures is markedly small and may not accumulate 
detectable differences of ROS. 
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5.5.4 Mitochondria 
 
 
 
Figure 5.11; Mitochondrial MFI for Day 14, 18 and 21 of cells treated with 5 and 
10% oxygen in comparison to control cultures. The mitochondrial MFI of cells at 
day 14 cells grown in 5% oxygen was almost 5 times higher than control cultures 
 
The mitochondrial MFI of Day 14 cells grown in 5% oxygen was almost 5 times higher 
than that of control cultures. This could mean that more mitochondria are produced in 
response to hypoxia or that mitochondria work at a higher rate since the assay works by 
accumulation. Since it was found to the contrary that oxygen utilization is lower under 
hypoxic conditions that the mitochondrial signal peaks on day 14 prior to mitochondrial 
expulsion and since early-onset enucleation has been recorded under hypoxic conditions 
(next section) it is supposed that the elevated MFI is a symptom of mitochondrial 
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clearance. Since there was no recorded upregulation HIF-1-α it is not sure by which 
mechanism cells produce this response.  
 
5.5.5 Marker profile 
 
 
 
Figure 5.12; Markers of interest (as specified during device cultures) for Day 14 
cells grown in static cultures at 5, 10 and 21% (control) oxygen. Cells did not 
exhibit the same fluctuations as shown in the device cultures, leading to speculation 
that the mild shears experienced within the device were the causation 
 
The predisposed markers of interest (CD34, CD45 and CD41a) which showed a 
significant response hypoxia in the cell culture device did not show an effect for the 
static culture conditions leading to the supposition that the mild long-term shears 
experienced during culture were the cause of these diversions. 
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5.5.6 Enucleation 
 
 
Figure 5.13; Percentage of enucleation exhibited by cells at days 14, 18 and 21 of 
the protocol grown in 5, 10 and 21% (control) oxygen. Cells grown in 5% oxygen 
exhibited higher enucleation than those grown in 10 or 21% oxygen. Cytospin 
images recorded of these cultures showed patches of extruded nuclei. NB. Scale 
bars are not included for these images since the cytospin procedure stretches and 
distorts cells (x40 magnification). 
 
 
As was shown earlier (Section 3.2.2) cell nuclei are continually extruded from day 12 
onwards but they are continually marked for apoptosis so that even at the peak of 
enucleation only a maximal 35% is recorded on flow cytometry plots. FSC/SSC flow 
cytometry images showed Day 14 CD34+ differentiating cells which were grown in 5% 
oxygen presented much higher rates of enucleation than those grown in 10 or 21% 
oxygen indicating early-onset enucleation under hypoxic conditions. This was 
confirmed by cytospin images which revealed large areas of extruded nuclei. The cells 
themselves appeared diffused, possibly due to imaging method (cytospin procedure 
distorts cells and the g-force causes the cells to lyse) and these factors combined could 
perhaps be part of a stress response to hypoxia. It might be that hypoxia is a trigger for 
enucleation which has been an issue for the in vitro generation of red blood cells using 
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pluripotent stem cells (not shown). Since hypoxia was also found to decrease the 
doubling time of pluripotent RC9b cells two-fold it may be that oxygen concentration is 
a key regulator (and enhancer) of haematopoietic development. This is something which 
should be investigated further.  
 
5.6 Summary 
 
Encouragingly device/ruthenium biosensor trials with J774 cells returned similar results 
to those found in literature, however many of the cited values do not express differences 
in the lag and log phases which were found experimentally to be very different. As this 
Chapter has shown oxygen utilization is dynamic throughout the life of the culture 
dependent on both biological and physical factors, therefore it should be monitored 
continuously. 
Although results are shown here for one trial with RC9b cells the microdevice was used 
several times in hypoxic conditions. Prior to contamination cells always appeared to 
proliferate wildly in comparison to incubator cultures. This is very exciting in terms of 
scale-up. As anticipated erythropoiesis was upregulated under hypoxic conditions and 
yielded more than double the number of cells. This is definitely something which 
should be revisited once the RC9b/SFC i55 cell lines have been stabilised. The oxygen 
consumption rate of 2.4 amol cell-1 sec-1 was very similar to that found for cord blood 
cells (2-3.5 amol cell-1 sec-1) which was encouraging since both these cell types 
expressed similar levels of mitochondria. It also reinforces metabolic similarity which is 
promising in terms of producing equivalent erythroid cells using different types of stem 
cells. 
Disappointingly CBS cells did not exhibit the same upregulation of erythropoiesis. 
However since erythropoiesis is upregulated by erythropoietin and this is added from 
day 0 of the CBS protocol (for RC9b this was not added until day 10) perhaps the signal 
was superseded. Given this and the results of the ROS there is no reason why CBS cell 
expansion should be improved under hypoxic conditions.  
It was however encouraging in terms of scale-up that following mitochondrial clearance 
oxygen concentration can be reduced significantly. This should prevent augmented 
bubble damage in bioreactor culture and ROS which have been shown to age red blood 
cells en vivo. 
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Chapter 6 – Shear Stress Results 
 
6.1 Introduction 
 
Under physiological conditions cells are subjected to a wide range of shear stresses due 
to persistent changes in local pressure and viscosity. This is particularly true of 
haematopoietic cells of which many types are mobile in the blood stream and therefore 
additionally exposed to changes in arterial and venous morphologies.  Additionally 
CD34+ cells are of fetal origin and it is unclear at which stage in their development 
differentiated cells are released to the fetal blood stream or indeed the shear stresses 
imposed by fetal circulation. Hence in this chapter differentiating CD34+cord blood 
cells were subjected to a range of shear stresses at progressive stages in their 
development in order to discover whether there was any observable effect on 
morphology, physiology, expansion and all-round cell health.  
 
6.2 Determining shear stress values 
 
Aside from exposing cells to physiological shear stresses (0-5000/s) it was important to 
also represent in vitro systems which were being used for (or projected for use on) the 
project. Small scale cultures were being carried out in 6-well plates or T-flasks under 
static conditions and therefore shear was considered as 0/s. Two scale-up vessels were 
purchased for use on the project; an Integra Cellspin with 500mL spinner flask and a 5L 
Celligen BLU bioreactor. Prior to experimentation both were analysed for shear stress 
levels using Comsol Multiphysics 4.4 computer fluid dynamics (CFD) software 
package. This work was completed with the assistance of Dr Alan McGuinn who 
worked as PDRA on the project and completed most of the drawings and mathematical 
modelling for the simulations. Experimental design, some drawings/simulations and 
data analysis were carried out personally. 
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6.3 Agitation rates 
 
In order to model shear stress inside the scale-up vessels it was necessary to estimate the 
agitation rate. At the time of experimentation the Integra Cellspin was already in use for 
CD34+ cord blood cells with agitation rate set at 15rpm however the Celligen BLU rate 
had to be estimated by traditional means. 
The ideal agitation rate should ensure turbulent regime and for stirred tank cultures this 
transitional Reynolds number is 104, yielding an agitation rate of 47 rpm 
(10,000*0.00078)/(991.348*(0.1)2). For sparged cultures this figure should then be 
reduced by 20%, leaving a final agitation rate of 37.5 rpm [40]. 
Since the Integra Cellspin was already running successfully a second more experimental 
approach was taken to estimate the agitation rate inside the Celligen BLU Bioreactor 
which reflected the Reynolds number calculated (2034). This was then applied to the 
Celligen BLU and the equation solved to find the agitation rate, which was calculated as 
9.56rpm. 
 
6.4 CFD modelling 
 
6.4.1 Integra Cellspin and Celligen BLU 
 
The Integra Cellspin 500mL spinner flask was measured accurately and its’ geometry 
copied into Comsol (Figure 6.1A&B). The model was then run using the following 
settings; Element size: Max 0.00532m, Min 0.001m, Growth rate 1.13, 2 Boundary 
layers, 132,530 elements, Viscosity 0.00078 N.s/m2, Density 991.348 kg m-3 at 15rpm 
for 30 seconds to ensure steady state was reached. The simulation was assessed for 
shear stress and the prevalent output calculated as 50-60s. 
The Celligen BLU Bioreactor was also measured accurately and its’ geometry copied 
into Comsol (Figure 6.1 C&D). The model was then run using following settings; 
Element size: Max 0.00795m, Min 0.0015m, Growth rate 1.13, 5 Boundary layers, 
645,056 elements, Viscosity 0.00078 N.s/m2, Density 991.348 kg m-3 at 37.5rpm for 10 
seconds to ensure steady state was reached. The simulation was assessed for shear stress 
and the prevalent shear rate output was calculated 140/s. The model was run a second 
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time at an agitation rate of 9.56rpm which gave an output of 50-60s, the same as the 
Integra Cellspin.  
 
 
Figure 6.1; CFD outputs for Shear Stress (A) and Velocity (B) in the Integra 
Cellspin as calculated by Comsol with the specified settings. Simulations were also 
completed for the Celligen BLU Bioreactor (C&D). The outputs were used in the 
experimental design of the capillary experiment 
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In addition to physiological shear stresses, the mean shear stress levels (60 and 140/s) 
for the scale-up vessels as calculated by Comsol were added to the experimental profile 
 
 
6.4.2 Capillary Tubes 
 
Optimum shear rate for mammalian cells is usually within the range of 0.2 and 3 N m-2 
but can be as high as 4 N m-2 in the blood stream.  Since differentiating CD34+ cells 
change in size and elasticity over the duration of the protocol and are intended for blood 
circulation, it was important to test up to the maximum rate. The following shear rates 
were chosen for assessment; 0/s, 60/s, 140/s, 250/s, 500/s, 1000/s, 2000/s, 3000/s, 
4000/s, 5000/s, incorporating en vivo, in vitro and optimum shear rates (obtained by 
dividing by viscosity).  A series of flow rates and diameters of PEEK capillary tubing 
were assessed by CFD to find corresponding internal mean shear rates.  Since 
capillaries are axisymmetric only half of the capillary was drawn into Comsol to 
increase solving power (Figure 6.2). 
 
 
 
 
Figure 6.2; Example of a CFD simulation showing top view shear stress contours 
inside 250µm ID tubing at a flow rate of 10µl/min. Image A shows that shear is 
variable at the entry region so a trajectory was drawn across the capillary (B) 
where flow was fully developed and the resultant data was averaged to gain a 
mean shear for each tubing size/flow rate. 
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Following the analysis two tubing sizes were chosen; 250µm and 500 µm. Reynolds 
numbers were then calculated to ensure laminar regime. 
 
 
Table 6.1; Summary of conditions found within 250µm tubing for selected flow 
rates. As flow rate increases so does the minimum to maximum shear range 
 
 
 
 
Table 6.2; Summary of conditions found within 500µm tubing for selected flow 
rates. There is a much higher/wider range of shear with increasing flow rate than 
for 250 µm 
Flow rate 
(uL/min)
Capillary 
ID (um)
Mean 
Linear 
Velocity 
(m/s)
Reynolds 
Number
Minimum 
Shear (s)
Maximum 
Shear (s)
Average 
Shear (s)
10 250 0.003395 1 6 116 60
23.5 250 0.007979 3 14.5 275 140
43 250 0.0146 5 26.9 511 250
85.5 250 0.02903 9 60 1059 500
171 250 0.05806 18 121 2298 1000
341 250 0.11578 37 276 5249 2000
515 250 0.17486 56 464 8817 3000
675 250 0.22918 73 658 12500 4000
855 250 0.2903 92 897 17000 5000
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6.5 Tubing Length 
 
JP Martinez et al. [81] found that tubing length had little/no effect on cells subjected to 
progressive shear stresses inside capillary tubing. Prior to experimentation this concept 
was tested using 3 lengths of tubing (0.5, 1 and 1.5m) and perfusing cell suspensions 
(2mL suspensions of 2x106 cells/mL) at a constant speed of 25µL/min. Suspensions 
were transferred to 6-well plates and left for 48 hours before counting and analysis by 
flow cytometry. No significant differences were found between any of the samples and 
only one tubing length (1m) was taken forward for the experiment proper. 
 
6.6 Experimental Set up 
 
As described previously a 2mL suspension of 4x106 cells (2 x106/mL) was drawn into 
10mL BD Plastipak syringe and connected to tubing using Upchurch Scientific 
connectors. The dispensing end of the tubing was attached to a T25 flask. Once all 
sterile connections were made the loaded syringe was removed from the hood and 
mounted onto the Aladdin syringe pump. The flow was started at the desired rate and 
stopped only once the entire cell suspension had been discharged. 1.5mL of the final 
Flow rate 
(uL/min)
Capillary 
ID (um)
Mean 
Linear 
Velocity 
(m/s)
Reynolds 
Number
Minimum 
Shear (s)
Maximum 
Shear (s)
Average 
Shear (s)
77 500 0.006536 4 6 114 60
180 500 0.015279 10 15 280 140
325 500 0.027587 18 29 543 250
650 500 0.055174 35 65 1240 500
1300 500 0.11035 70 157 2984 1000
2600 500 0.22069 140 395 7505 2000
3950 500 0.33529 213 701 13300 3000
5305 500 0.4503 286 1057 20100 4000
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cell suspension was then removed by pipetting (the rest discarded) and transferred to a 
6-well plate. Each well was topped up with 1.5mLs to a final volume of 3mL/well. The 
process was repeated for each flow rate before transferring the 6-well plate to a 37°C 
5% CO2 incubator and leaving for 48 hours before analysis. The cells were counted at 
T0 and again at T48 at which point they were also analysed by flow cytometry (for 
antigenic markers, apoptosis, and necrosis) and cytospin. 
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6.7 Expansion 
 
  
Figure 6.3; D11 cells exposed to consecutive shear rates in 250µm capillary tubing. 
Unexpectedly cells were prone to lyse at shears <1000/s. It was supposed that this 
was due to entry effects 
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Figure 6.4; D11 cells exposed to consecutive shears in 500µm tubing. Cells were 
less prone to entry effects. Peak shear appeared to be 140/s immediately following 
the experiment  
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At this stage in the protocol cells are large (11-12µm diameter), mostly nucleated and 
low in elasticity. Images captured immediately following the experiment for 250µm 
tubing revealed that unexpectedly, cells were prone to lyse at shears <1000/s (Figure 
6.4). It was supposed that this was due to ‘entry affects’ since CFD profiles had shown 
that narrow capillaries exhibit concentrated areas of elevated shears near the entry 
region. In order to compensate for this effect a second larger tubing size (500µm, Figure 
6.5) was used and as shown cells appeared improved for 140-500/s.  
Cell counts for 60-500/s in 250µm tubing were hence disregarded in terms of expansion 
although the marker profiles were still experimentally interesting (Section 6.8). 
 
 
 
Figure 6.5; Cell expansion of Day 11-13 cells subjected to progressive shears (60-
5000s) inside capillary tubes in triplicate. The red line indicates the average cell 
expansion for static cultures (0s). Almost all shear conditions resulted in reduced 
expansion, particularly 60/s. The optimum shear was 140/s as indicated by the 
arrow 
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Ordinarily day 11-13 fold-expansion is 2-3.5 and encouragingly most of the cultures lie 
within this range. The cells showed marginally improved expansion at 3000 and in 
particular, 140/s. 
 
 
Figure 6.6; Cell expansion of Day 15-17 cells subjected to progressive shears (60-
5000s) inside capillary tubes in triplicate. The red line indicates the average cell 
expansion for static cultures (0s). Almost all shear conditions resulted in reduced 
expansion, particularly 60/s. The optimum shear was 140/s as indicated by the 
arrow 
 
Day 15-17 showed similar patterns of expansion to day 11-13 with almost all cultures 
negatively affected by shear and 140/s as the optimum. Expansion during this period is 
usually 0.6-0.9 and cultures show a lesser capacity to recover, most likely due to 
enucleation.  
Day 18-20 perhaps shows the most candid effect of shear on cells in terms of abundance 
since by this point 65-75% of cells have lost the ability to proliferate. The optimum 
shear is again 140/s with the range of 140-500s also reasonable. Expansion seems to 
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increase gradually from 1000-4000s showing that cells are also amenable to high shears 
experienced in the blood stream. 
 
 
Figure 6.7; Cell expansion of Day 18-21 cells subjected to progressive shears (60-
5000s) inside capillary tubes in triplicate. The red line indicates the average cell 
expansion for static cultures (0s). All shear conditions resulted in reduced 
expansion, particularly 60/s. The optimum shear was 140/s as indicated by the 
arrow. 
 
Based on this data there is a strong case for 140/s (0.11 N m-2) as the optimum shear for 
stirred tank bioreactor culture. However it was also necessary to see if shear had an 
adverse effect on differentiation. 
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6.8 Marker profile 
 
6.8.1 Platelet markers 
 
As was shown in earlier sections it was suspected that mild shears induced synthesis of 
platelets. The relationship between CD41a and shear stress appeared well-defined on 
flow cytometry plots (Figure 6.8) however only 28% of samples presented a correlation 
at the P ≤ 0.05 (*) level. 
 
 
 
Figure 6.8; Flow cytometry dot plots of day 17 CD36/CD41a stained cord blood 
cells which had been (A) untreated or 0/s (B) subjected to 500/s (C) 1000/s (D) 
2000/s of shear stress. It is clear from the plots that while CD36 seems unaffected  
CD41a decreases as shear increases. This relationship was significant at the P ≤ 
0.00 (***) level, correlation value -0.941 
 
Nevertheless there is a visual correlation between CD41a and shear stress. Since CD41a 
is also an early stage haemangioblast marker CD42b and GPVI were added to the panel 
in order to confirm presence of platelets. Figures 6.9-6.11 show that for each of the 
time-scales tested (D11-13, D15-17 and D18-20) there is a noticeable increase in 
platelet markers in comparison to the control cultures. At D11-13 the increase is minor, 
with a maximal 11% of the cell population. The most affected stages of the protocol are 
D15-17 and D18-20 with average populations of 38% and 31% respectively.  
 
142 
 
Shear (s)
0 60 140 250 500 1000 2000 3000 4000 5000
P
er
ce
nt
ag
e 
of
 P
op
ul
at
io
n
0
2
4
6
8
10
12
CD41a 
CD42b 
GPVI 
 
 
Figure 6.9; Average platelet marker profile following day 11-13 experiments. 
CD41a and GPVI are elevated in comparison to the control (0/s) peaking at 500 
and 140s respectively. CD42b remains relatively low. 
 
Since platelets markers only rise to 11% for day 11-13 of the protocol it is proposed that 
either megakaryocytes necessary to produce platelets are in precursor form and not able 
to produce platelets or that these cells are more robust/better able to regenerate. Day 15-
17 and day 18-20 cells exhibited much higher platelet marker peaks as shown in Figures 
6.10 and 6.11. 
 
143 
 
Shear (s)
0 60 140 250 500 1000 2000 3000 4000 5000
P
er
ce
nt
ag
e 
of
 P
op
ul
at
io
n
0
10
20
30
40
50
CD41a 
CD42b 
 
 
Figure 6.10; Average platelet marker profile following day 15-17 experiments. 
CD41a and GPVI are elevated in comparison to the control (0/s) peaking at 1000s. 
CD42b remains relatively low. GPVI data is not available for day 15-17 
experiments since this was only added to the panel mid-way through 
experimentation 
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Figure 6.11; Average platelet marker profile following day 18-20 experiments. 
GPVI is elevated in comparison to the control (0/s) peaking at 250s. CD41a is less 
prolific but nevertheless elevated in comparison to control cultures peaking at 
1000s.  CD42b has a marginal peak at 140s. 
 
Higher platelet markers would indicate presence of platelets and it was hoped that this 
would be confirmed by the cytospin images. It is feasible that platelets should be 
released in response to shear stress and cellular damage as is their action en vivo. 
However curiously, as was shown in figure 6.8, in some instances whole cell 
populations expressed platelet markers and which seemed unrealistic. Moreover, 
platelets 2-3µm in diameter, are much smaller than erythrocytes 8-10µm and hence two 
cell populations should have been visible on the flow cytometry images. It was 
hypothesized that the platelets could become adhesive to damaged erythrocytes as is 
shown in Section 6.10. 
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6.8.2 Other markers 
 
The rest of the panel (CD45, CD34, CD31, CD43, CD71, CD235a and CD36) were also 
tested using the Pearson method however no correlations were found. Hence it can be 
assumed that shear stress has no effect on haematopoietic development, only it induces 
megakaryocytes to generate platelets.  
 
 
6.9 Apoptosis and necrosis 
 
 
Figure 6.12; Apoptosis and necrosis profiles of cells exposed to increasing shear 
stress. There is a dip in apoptosis at 140/s which makes a strong case for optimum 
shear. Apoptosis peaks at 1000s coinciding with peak platelet synthesis 
 
Apoptosis and necrosis were recorded at progressive shear stress using flow cytometry.  
There was a marked dip in apoptosis at 140s which reinforces the case that this may be 
the optimum shear for scale-up culture. Following this there was a peak in apoptosis 
which corresponded to platelet synthesis. Apoptosis dropped off from 3000-5000s 
which was unexpected but perhaps this is due to erythrocytes being adapted to high 
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shear stresses such as those found in the blood steam. This could also be a product of 
experimental design as shall be discussed in Section 6.12. 
 
6.10 Enucleation 
 
No correlations were found between shear stress and enucleation. Although this could 
be seen as a disadvantage since enucleation cannot be mechanically manipulated, it 
could also be advantageous since it would be unaffected by scale-up. This result was 
surprising since others have implicated mechanical shear stress as a stimulus, it may be 
that only long term shears affect enucleation and this should be investigated further. 
 
6.11 Morphology 
 
Day 11-14 cells which were subjected to increasing shear stresses showed no 
discernible morphological differences. This was surprising since at this stage in the 
protocol cells are larger, rounder and less elastic than the latter, however they show a 
greater capacity to regenerate as was shown in the expansion data. There were several 
discernible morphological effects of shear stress on latter stage (post day 15) 
differentiating CBS cells which are shown in figure 6.13. Many of the cells appear 
elongated (6.13A) which is most likely a result of the flow profile inside capillary tubes. 
 
 
 
 
 
Figure 6.13; Velocity profile inside capillary tubing. Under laminar flow conditions 
a parabolic velocity curve develops where flow is static at the capillary wall and 
increases toward the tubing centre. Shear stress is highest at the capillary inlet 
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since before flow becomes fully developed cells can come into contact with the no-
slip condition at the capillary wall 
 
Since mature red blood cells are known to be elastic and slip through blood capillaries 
with diameters 5-10µm at shear stresses up to 4 N m2 it is surprising that CBS derived 
erythroid precursors show elongation 48 hours post-experiment. Of course since they 
have lost their nuclei they have lost their ability to regenerate however it would seem 
that CBS derived erythroid cells are not as malleable as adult erythroid cells and are 
more susceptible to damage by shear stress. This may be grounds for further 
investigation since it is important that manufactured erythrocytes are suitability 
characterized and their properties well-known prior to clinical trials 
 
 
 
Figure 6.14; (A) In many cases cells are elongated due to parabolic flow profile 
inside capillary tubing. (B) Cells appear ‘patchy’ although this could be an effect 
of cytospin which can distort cells. (C&D) Cells exhibit patches of purple which 
could be clusters of platelets. NB. Scale bars are not included for these images 
since the cytospin procedure stretches and distorts cells (x40 magnification).  
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Figure 6.14B shows ‘patchy’ cells which could indicate development of vacuoles, a 
hallmark of cellular stress. Pictures C and D show unusual patches of purple on the cells 
which had not been seen prior to shear stress experiments. It is assumed that these 
patches are in fact the platelets which were recorded during flow cytometric analysis. 
Hence it is proposed that megakaryocytes mature by day 15 of the protocol and produce 
platelets in response to shear stress and/or stress signals released by damaged erythroid 
precursors. The platelets then attach to damaged areas of the cells. Although to our 
knowledge this mechanism has not been found previously in CBS erythroid precursors 
the adhesive properties of platelets and their abilities to repair cell damage are well 
documented.  
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6.12 Summary 
 
The use of CFD to estimate shear stress and other unknown physical parameters is 
becoming widely useful in scale-up studies. However one drawback to this method is 
that the only way to be certain of its accuracy is to back it up with experimental proof 
which seems counterintuitive. The estimates obtained for the Celligen BLU bioreactor 
and Integra Cellspin were realistic in terms of more traditional methods of calculation 
and were therefore considered experimentally sound. Laminar flow profiles inside 
capillaries are simple and were considered accurate. As was shown in figure 6.13 once 
flow is fully developed cells should travel in the centre of the tubing but this is not true 
for the entry region.  
It was expected that entry effects may contribute to some cellular damage, however it 
was unexpected that it would be so detrimental for 0-500s conditions in the 250µm 
tubing. These effects were no so pronounced in similar studies, although the flow rates 
were higher, which was the rationale for adding the second 500µm tubing size. It is 
extremely important to know the effects of shear stress on differentiating cells, since it 
has been found to alter cell type and could alter end product in a scale-up process. 
However this experiment would be better suited to a microdevice in which the shear 
stress profile is more defined/known and the entry region is better designed. 
Regardless the experiment was successful since it obtained its objectives. The high cell 
counts and low apoptosis rate at 140s makes a strong case for an optimum shear of 0.11 
N m-2. This is much lower than other cell types which generally lie in the range of 0.2-3 
N m-2 but perhaps this is due to the en vivo environment of CBS cells where they are 
unlikely subjected to high shears.  
Although it was encouraging to find a candidate condition for optimum shear, 
conversely the synthesis of platelets under mild shear stresses was ominous in terms of 
scale-up. Augmented platelet production could contaminate the end product which may 
then require a further purification step. They may also deplete the media of nutrients 
necessary for erythrocyte growth. 
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Chapter 7 – Discussion and Conclusion 
7.1 Discussion 
 
RC9b and SFC i55 cell lines were successfully differentiated and expanded at 
Mountford Laboratories but unexpectedly the process could not be repeated at Heriot 
Watt University or indeed any other University in the consortium. This conundrum 
remains unexplained however there are several factors which may have contributed.  
Firstly, maintaining pluripotency. Although clinical grade pluripotent stem cells were 
supplied by Roslin in the first instance, new banks were created at University of 
Glasgow and subsequently transferred to Heriot Watt University. Each passage induces 
a small amount of spontaneous differentiation which reduces pluripotency. This can 
build up over the consecutive passages necessary for cell banking/thawing and can 
easily become augmented since cell culture health is assessed primarily by morphology 
(a subjective, unstandardized measure) and is easily overlooked. Spontaneous 
differentiation can also occur if the cells are not thawed quickly and may be vulnerable 
when in transit on dry ice.  
Maintaining pluripotency of stem cells is a well-known challenge in regenerative 
medicine. Traditionally pluripotent stem cells were grown on MEF feeder cells which 
continuously secrete growth factors over the lifetime of the culture in response to 
paracrine signals. Feeder cells however are not amenable to GMP-compliant scale-up 
culture since they are animal derived, posing the potential transmission of animal 
pathogens. Although human equivalents have been trialled they do not maintain 
pluripotency as well as MEFs and require supplementary growth factors.  
Regardless of origin feeder cells grow in monolayers with stem cells as a co-culture 
which would pose an additional challenge in cell separation prior to initiation of the 
differentiation culture. The secretome composition of the feeder cells is also unknown 
(this is also true of serum) and in order to reduce variation in end product these 
components must be removed. It is for these reasons that feeder-free serum-free culture 
systems for pluripotent stem cells are being developed throughout the field however this 
has inflicted a new set of challenges. Since feeder cell excretions are living, dynamic 
responses to paracrine signals emitted by pluripotent stem cells, they are impossible to 
truly replace through the use of artificially added growth-factors. Additionally many 
growth factors are cytokines which generally have short half-lives and are readily 
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degraded when exposed to adverse environmental conditions. Even slight variations in 
temperature and light can render them inefficient which could have a detrimental effect 
on the pluripotency of the culture. 
As was shown in Chapter 3 the pluripotency of the RC9b and SFC i55 cells was 
inconsistent in comparison to the Mountford Laboratory cells and may have impacted 
on later stages of the protocol. Cells which have lost their pluripotency have essentially 
undergone germline specification into any of three germ layers (mesoderm, endoderm 
or ectoderm) and since this transition is unidirectional, any which have specified to an 
erroneous lineage are not available for haematopoietic differentiation, decreasing 
product yield from the onset. 
 
Conversely many of the differentiations attempted at Heriot Watt University were 
performed using stem cells which were sufficiently pluripotent (as determined by 
Mountford Laboratories) yet the same overall fold-expansions were never achieved.  
Day 0-3 embryoid bodies were successfully formed and obligatory expansion attained 
but for the for the period day 3-10 only an average 8-fold expansion was achieved in 
comparison to 20-50-fold at University of Glasgow. The marker profile 
(CD71/CD235a/CD43/CD31) specified presence of haemangioblasts and early 
erythroid progenitors in accordance with Mountford Laboratory data. However CD34 
(haematopoietic stem cell) and CD45 (common leukocyte antigen) were 
uncharacteristically high. Since CD45 appears on almost all haematopoietic cells except 
erythrocytes and CD34 is a haematopoietic stem cell marker it could be that the cells 
were in a state of arrested development and did not suitably progress from germline 
specification to lineage commitment. Several novel molecules are introduced at day 2/3 
of the protocol (FGF-α, SCF, IGF2, TPO and IBMX) one/some of which could be 
responsible for this developmental failure. Perhaps the most likely candidate would be 
stem cell factor (SCF) which is first added day two of the protocol and is responsible for 
haematopoietic commitment and proliferation. Should this cytokine become inoperative 
it would result in suspension in the haemangioblastic state and lack of proliferation as is 
was evident in the data. However 3-Isobutyl-1-methylxanthine (IBMX) added on day 3 
of the protocol elevates cAMP levels to activate protein kinase A (PKA) which 
increases differentiation. Since IBMX and consequently PKA modulate timing of 
differentiation, if IBMX is defective then this could also result in suspension in the 
haemangioblastic state. Morphologically the cells looked to be progressing through 
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differentiation in the required way and CD71 (transferrin marker involved in 
haemoglobin import exclusively found on erythroid lineage cells) was normally >90% 
so it could be that it was a timing issue which effected proliferation and otherwise they 
would develop normally only at a slower rate. It is puzzling that morphologically cells 
differentiated at Heriot Watt University are identical to the Mountford Lab cells aside 
from proliferation. Perhaps the cells were not in arrested development at all and were 
only deficient in proliferation alone due to inactive insulin-like growth factor (IGF) 
which is not involved in haematopoiesis per-se but is a mitogenic hormone which 
ordinarily stimulates proliferation and cell survival.  
 
In reality the absence of fold-expansion could be attributed to any of the 18 growth 
factors used during the protocol, especially due to the instability of cytokines in culture. 
Although every effort was taken to standardize the growth factors (and indeed all 
aspects of the differentiation culture) inconsistencies in supplier lots, preparation, 
storage and handling may have affected the potency of these molecules and may have 
impacted on the outcome of the differentiation culture. Further to this, differences in 
local physical environment imposed by experimental equipment and operator handling 
may have also impacted on the process. As was shown in Chapter 3 even the mild 
shears experienced by external laboratory equipment can induce unwarranted responses 
in differentiation culture (platelets). It could be (and often is) an oversight in the 
physical environment of the cell culture and/or their reagents which are the culprits of 
variation.  
 
The ground covered with pluripotent stem cells in the initial stages of this research 
could easily be disregarded but the results are significant and scientifically relevant to 
this study. They highlight universal, reoccurring issues in the manufacture of clinically 
useful pluripotent-derived cells; that stem cells are often unpredictable and the resultant 
variabilities are extremely difficult to eradicate. Results regarding these issues are 
seldom published and in order to transform benchtop stem cell cultures into clinically 
and commercially viable products all-round improvements in communication, cross-
training and method standardization between laboratories are necessary. 
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Fortunately CD34+ cord blood cells presented an ideal solution to the problems with 
pluripotent stem cells. Since they are already lineage committed pluripotency issues 
were eradicated and their differentiation required less growth factors; predominantly 
hormones which are generally more stable in culture. From commencement of work 
with CBS cells expansion and differentiation were routinely achieved in-line with 
Mountford Laboratory data. Although the experiments in this research were designed 
for use with pluripotent stem cells they were successfully adapted for use with CBS 
cells. 
 
Two devices were designed for use on this project, initially a microfluidic device. The 
ultra-scale down approach was successful in reducing reagent costs and was easily 
integrated into a microscopy platform for in-situ imaging.  
However the microfluidic device was difficult to develop.  Initially a lot of time should 
be spent in the design stage, assessing requirements for cell growth, analysis method 
and anticipating potential problems. Two of the major difficulties experienced during 
the scope of this research were contamination and leakage as is common with cell 
culture microdevices. Many of these problems could have been prevented if more time 
had been spent in the design stage but this was owing to inexperience. Although three 
forms of sterilization were used during the scope of this research (ethanol, UV and 
autoclave) only autoclaving resulted in a 100% success rate and hence thermostable 
materials should be prioritized when selecting materials for microfluidic devices. 
Leaking is always a reoccurring issue in microfluidics, however carefully considering 
available bonding methods and standardizing connections with commercially available 
microfluidic fittings are preventative measures. 
The analysis method should also be carefully considered during the designing stage. 
Microfluidic devices are not ideal for use with flow cytometry analysis (and indeed 
many other laboratory analysis methods), particularly due to the unexpected lack-lustre 
fold-expansion, but also because the cells must be removed from the device prior to 
testing. Therefore a second ‘mesofluidic’ device was implemented which addressed 
both of these issues. 
 
This device was intended for in-situ analysis of adherent pluripotent cells however this 
was not amenable to CBS suspension cells due to the flow and vibration of external 
equipment which made them difficult to visualise. The device did however facilitate the 
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use of biosensors which was one of the main aims of the project. Retrospectively 
biosensors are difficult/time-consuming to develop and are not always amenable to 
sterilisation methods necessary for cell culture. The ruthenium oxygen sensor was the 
only biosensor which could be sterilized (by ethanol) and remain active. The glucose 
sensor facilitated a thin film of poly-allyl-amine hydrochloride (PAH) and poly-sodium 
4-styrenesulfonate (PSS) which was stripped by ethanol. The HPTS sensor was never 
successfully fabricated due to the unsuitability of the PDMS polymer.  
None of the biosensors trailed could be sterilized by autoclave which should have been 
considered in the design stage of the project. Regardless the mesofluidic device and 
oxygen (ruthenium) biosensor were used successfully to analyse the effects of oxygen 
concentration on differentiating stem cells as was intended. 
 
As shown in Chapter 1 Wagner et al reported that different cell types utilize oxygen at 
different rates. J774 cells were reported as 31 amol cell-1 sec-1, followed by HL60 cells 
11.5 amol cell-1 sec-1 and red blood cells 4 x10-5 amol cell-1 sec-1. It was unclear where 
stem cells would lie on this scale although profiling of mitochondria (Chapter 3) found 
day 8 CBS cells and RC9b cells to be 6  and 3 times fewer than J774 and HL60 cells 
respectively.  
Experimentally the oxygen consumption rate for J774 cells was found to be between 13 
and 92 amol cell-1 sec-1 (dependent on lag/log phase), 2.4 amol cell-1 sec-1 for RC9b 
cells a maximum of 3.5 amol cell-1 sec-1 for CBS cells which equates to 3-5 times less 
oxygen. Hence although mitochondria presence can be used to ascertain ranking of 
oxygen utilisation in different cell types it is not accurate in predicting the consumption 
rate. The method used for detecting mitochondria relates to accumulation of the 
fluorescent probe due to the ion potential maintained by the proton gradient. Hence the 
fluorescence intensity could be affected not only by number of mitochondria but 
upregulated action. As was shown in Chapter 4 oxygen utilization is downregulated in 
hypoxic conditions indicating a metabolic switch to glycolysis, so mitochondrial action 
is dynamic and dependent on its physical (and probably biological) environment. 
It was found that oxygen consumption rate dropped further to 2 amol cell-1 sec-1 at day 
15-18 following the expulsion of mitochondria. However this is far off (50000 times) 
the 4 x10-5 amol cell-1 sec-1 predicted for red blood cells which indicates considerable 
metabolic differences in CBS derived erythroid precursors.  
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Once the differentiating CBS derived erythroid precursors have expelled their nuclei 
they are considered reticulocytes, the final cellular stage before erythroid maturation. It 
is difficult to tell them apart in cytospin pictures but CD71 is a marker for reticulocytes. 
Even at day 18 CD71 is >90% which indicated that the cells are not maturing into 
erythrocytes. Reticulocytes retain some mitochondria which may explain the difference 
in oxygen utilization found during this research. This is problematic on two counts; 
firstly if the reticulocytes are not maturing into erythrocytes then they will not behave in 
the same way as adult red blood cells and therefore may not be suitable candidates for 
blood transfusion. Secondly, since reticulocytes contain mitochondria (which contain 
DNA) even if these cells were found to be clinically useful, once irradiated (which is the 
proposed sterilisation method for the project) they may lose their functionality since the 
roles of mitochondria in erythroid precursors are not entirely understood.  
Alternately since cord blood derived stem cells are slightly morphologically, 
phenotypically and physiologically dissimilar from adult bone marrow derived stem 
cells, it could be that the erythroid cells they generate will also be different. 
Assumptions are often made in stem cell therapy research that cells generated will be 
clinically safe and useful, however there are clues in this research (and others) that this 
may not be the case. As was shown in Chapter 3 SFC i55 cells have 2-3 times more 
mitochondria than RC9b cells and it has been found in other studies that they become 
mutated during reprogramming. Red blood cells generated in this study do not seem to 
develop or behave in the same way as red blood cells generated from adult 
haematopoietic stem cells. Hence more research should be performed to ensure the 
safety and compliance of opposing stem cell types prior to initiation of differentiation 
studies. 
 
The expansion profiles of cells cultured at 5 and 10% oxygen in the static cultures were 
only marginally affected in comparison to the control cultures. There were no 
differences in expansion following day 15 in the differentiation process for cells 
cultured at 10% oxygen which specifies an advantage in terms of scale-up; the 
traditional bioreactor sparge rate (40%) could be reduced by half preventing bubble 
damage. It is surprising that the expansion level diminished under hypoxic conditions 
prior to day 15 since CBS cells have a low oxygen consumption rate and erythropoiesis 
is known to be upregulated under hypoxic conditions. It is likely that erythropoietin 
which is already added to the media accounts for this action already or as earlier 
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mentioned, it could be that there are broader differences in CBS and AS cells than 
initially thought. Since these stem cells reside in different niches they may respond to 
divergent physiological cues. 
 
For example, it was unexpected that higher levels of Hif-1-α were not recorded during 
the hypoxia experiments. Initially it was expected that the analysis method for Hif-1-α 
was not sufficient and that Western Blot should be used. Although this is a possibility, 
flow cytometry is a valid form of analysis for Hif-1. It was also considered that the 
oxygen levels used in the experiments were not low enough to warrant a response. 
However it was shown during the course of this research that oxygen utilization was 
downregulated under hypoxic conditions, which is indicative of a hypoxic response. A 
third explanation is that in contrast to other stem cell types, CBS cells do not upregulate 
Hif-1 in response to hypoxia and they have another mechanism for hypoxic response. 
This is unlikely since Hif-1 is highly conserved and is the master regulator of hypoxia in 
all known human cell types. This warrants further investigation, since such fundamental 
differences in stress responses could be detrimental to the development of stem cell-
derived red blood cells. 
  
Furthermore AS-derived red blood cells are aged by accumulative ROS which is one of 
the mechanisms by which they are then marked for apoptosis after 120 days in 
circulation. For cells produced during this project the survival rate was poor post day 18 
(0.6-0.9%) and most cells were marked for apoptosis by day 21 when cultures were 
ceased. Since there is an increase in ROS at day 21 in comparison to day 18 it is 
possible that this accumulation contributes to premature cell death. ROS were recorded 
as high for day 11-14 but were diminished post day 15 indicating that ROS species are 
produced as a by-product of mitochondrial metabolism. Since the cells are stalled in 
reticulocyte form (which maintain some mitochondria) there may be an abnormal 
accumulation of ROS which is detrimental to the cells. AS-derived red blood cells 
neutralise ROS via cytosolic and membrane bound catalase, glutathione peroxidase and 
peroxiredoxin-2 so it would be interesting to see if reticulocytes retain these enzymes. 
The life-span of CBS-derived red blood cells must be improved significantly before 
they can be considered ideal candidates for cellular therapy.  
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The shear stress experiments were conducted in capillary tubes of which the shear 
profile was estimated using CFD. Although it was hoped this would provide an accurate 
profile of the cells’ shear stress environment the results indicate otherwise. The 
expansion results for 60s were extremely low for both tubing types. Although it is 
possible that very low shears are highly detrimental to cells it is more likely that these 
results were caused by entry effects as described in chapter 6. The low flow rate at 60s 
(10-77 µL/min) coupled with the small entry region may have caused the cells to lyse 
upon contact with the no-slip layer. Furthermore the expansion profiles of the day 11-14 
cells (in particular) and day 15-18 cells are highly erratic, although this could be 
accounted for by the cells’ capacity to proliferate (prior to enucleation) which varies 
naturally from culture to culture. In order to make the experiment more robust a shear 
capillary microfluidic device would be better suited in which the shear stress 
environment could be accurately estimated. Cells should also be counted and analysed 
for apoptosis/necrosis immediately following the experiment and again every 24 hours 
post-experiment ascertain the true extent of damage and recovery. Samples of cells 
analysed by flow cytometry 24 hours after exposure to shear stress showed a high level 
of platelet markers which diminished over time (not shown) and so it is suspected that 
in most cases cells are able to recover. The experiment could be improved by 
completing flow cytometric analysis every 24 hours to track resilience.  
 
This research has presented the presence of platelet markers for mild long-term shear 
stresses as imposed by the intermittent vibration of the mesofluidic device (-80°C 
freezer) and short-term shear stresses in capillary tubes. Since platelets were not 
identified on the cytospin images it is suspected that the platelets attach to damaged 
areas of the haematopoietic cells as is the case with en vivo blood vessels and other 
types of cells. As shown in the cytospin images, some cells exhibit vacuoles, a hall-
mark of cellular stress and others exhibit areas of purple which could be aggregates of 
platelets. This is backed-up by the flow cytometry data which signifies that between 
shears of 140 and 1000s (0.1 and 0.8 N m-2) platelets (or their markers) are highly 
upregulated. These results are somewhat puzzling since for most cell types this is the 
optimum shear range. Additionally cytospin images revealed that 48 hours post 
experiment the CBS derived red blood cells had not regained their round/discoid 
morphology. AS cell-derived red blood cells are known to be highly elastic, able to 
squeeze through blood capillaries 5-10µm and withstand shears of up to 4 N m-2. Since 
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CBS-derived red blood cells lack deformability, it can’t be said that they are 
physiologically unalike adult red blood cells. Again this could be due to the fact that 
they are stalled in reticulocyte form or it could be that the red blood cells produced by 
CBS cells are more dissimilar to those produced by AS cells than was originally 
thought.  
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7.2 Conclusion 
 
The microfluidic approach used for the purposes of this research was successful in 
reducing experimental costs and providing a continuous means of online monitoring of 
oxygen consumption with cell growth for the duration of the differentiation culture. 
Although it was hoped this set-up would implement other types of biosensors it was 
found that those selected were difficult to develop and/or were not complaint to 
continuous cell culture and sterilisation techniques. Further work is needed in this area 
to produce viable options for biosensors for use with cell culture. 
It was hoped that this research would produce optimum parameters for stirred tank 
bioreactor differentiation of red blood cells from human pluripotent stem cells. This was 
not possible due to the non-transferrable process of haematopoietic differentiation of 
RC9b and SFC i55 cells. This work along with others has identified the huge challenge 
in transferring said processes between laboratories and standardizing procedures prior to 
industrialization. Particularly in the case of stem cells which have proven so 
unpredictable and unreliable though-out the field. It is believed that these obstacles can 
be overcome with more in-depth analyses of different types of stem cells prior to 
initiation of differentiation studies.  
The pluripotent stem cell lines were replaced with CD34+ cord blood stem cells which 
were much easier to culture and the data was reproducible throughout the consortium.  
It was possible to estimate the optimum oxygenation (40% day 11-14 and 20% post day 
15) and agitation rate (37.5rpm based on expansion) for the haematopoietic 
differentiation of CBS cells in the 5L Celligen BLU bioreactor, as was one of the main 
aims of the project, however this research has found that this process is not yet ready for 
scale-up and more time must be spent in the development stage. 
Firstly it is projected that the low shears imposed by bioreactor culture may induce 
synthesis of platelets which could be detrimental to the culture in terms of nutrient 
depletion and impact on purity of end product. This would require an additional 
processing step which can be costly and time-consuming to develop.  
More importantly this research has highlighted that there are broader differences than 
initially thought between different types of stem cells and their products. This study has 
shown the CBS-derived red blood cells generated may not be clinically safe or useful 
due to their many metamorphoses from adult haematopoietic stem cell derived red 
blood cells. In order to make this a GMP-compatible scalable process more work must 
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be done to develop the protocol to ensure the end product is clinically viable red blood 
cells. An in-depth analysis of stem-cell derived red blood cells must be undertaken 
which elucidates and diminishes their physiological and metabolic differences. 
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